Insomnia and mechanistic pathways to atherosclerotic CVD in HIV by Polanka, Brittanny M.
INSOMNIA AND MECHANISTIC PATHWAYS TO  
ATHEROSCLEROTIC CVD IN HIV 
by 
Brittanny M. Polanka 
 
A Dissertation 
Submitted to the Faculty of Purdue University 
In Partial Fulfillment of the Requirements for the degree of 
 
Doctor of Philosophy 
 
 
Department of Psychology at IUPUI 
Indianapolis, Indiana 
August 2020 
  
 2 
THE PURDUE UNIVERSITY GRADUATE SCHOOL 
STATEMENT OF COMMITTEE APPROVAL 
Dr. Jesse C. Stewart, Chair 
Department of Psychology 
Dr. Adam T. Hirsh 
Department of Psychology 
Dr. Tamika C.B. Zapolski 
Department of Psychology 
Dr. Samir K. Gupta 
Indiana University School of Medicine, Department of Medicine 
 
Approved by: 
Dr.  Jesse C. Stewart 
 
 
 
 
 3 
TABLE OF CONTENTS 
LIST OF TABLES .......................................................................................................................... 5 
LIST OF FIGURES ........................................................................................................................ 6 
INSOMNIA SYMPTOMS AND BIOMARKERS OF MONOCYTE ACTIVATION, 
SYSTEMIC INFLAMMATION, AND COAGULATION IN HIV: VETERANS AGING 
COHORT STUDY .......................................................................................................................... 7 
Abstract ........................................................................................................................................ 7 
Introduction .................................................................................................................................. 8 
Methods...................................................................................................................................... 10 
Study design, setting, and participants .................................................................................. 10 
Measures and procedures ....................................................................................................... 10 
Statistical analysis .................................................................................................................. 13 
Results ........................................................................................................................................ 14 
Participant characteristics ...................................................................................................... 14 
Insomnia symptoms and sCD14 ............................................................................................ 15 
Insomnia symptoms and IL-6 ................................................................................................ 15 
Insomnia symptoms and D-dimer .......................................................................................... 15 
Discussion .................................................................................................................................. 16 
References .................................................................................................................................. 20 
ASSOCIATIONS OF SLEEP DISTURBANCE WITH MARKERS OF INFLAMMATION, 
COAGULATION, AND ENDOTHELIAL DYSFUNCTION OVER TIME IN HIV................. 30 
Abstract ...................................................................................................................................... 30 
Introduction ................................................................................................................................ 31 
Methods...................................................................................................................................... 32 
Study design, setting, and participants .................................................................................. 32 
Measures and procedures ....................................................................................................... 34 
Statistical analysis .................................................................................................................. 36 
Results ........................................................................................................................................ 37 
Participant characteristics ...................................................................................................... 37 
Changes over time in the exposure and outcome variables ................................................... 37 
 4 
0-to-12-week changes ............................................................................................................ 38 
12-to-24-week changes .......................................................................................................... 39 
Sensitivity analyses ................................................................................................................ 39 
Discussion .................................................................................................................................. 40 
References .................................................................................................................................. 44 
APPENDIX ................................................................................................................................... 54 
 5 
LIST OF TABLES 
Table 1.1 Characteristics of Veterans with HIV in the VACS Biomarker Cohort (N = 1,542) ... 25 
Table 1.2 Biomarker Levels across Insomnia Symptom Categories of Veterans with HIV in the 
VACS Biomarker Cohort .............................................................................................................. 27 
Table 1.3 Associations of Insomnia Symptoms Categories with sCD14, IL-6, and D-dimer levels 
in Veterans with HIV in the VACS Biomarker Cohort (N = 1,542) ............................................ 28 
Table 2.1 Participant Characteristics at Study Entry by Analytic Cohort .................................... 48 
Table 2 2 Sleep Disturbance and Biomarker Values at Each Time Point by Analytic Cohor ...... 49 
Table 2.3 Sleep Disturbance and FMD Values at Each Time Point by Analytic Cohort ............. 50 
Table 2.4 Multivariate Linear Regression Models Examining Associations of 0-to-12-Week 
Changes in Sleep Disturbance with 0-to-12-Week and 12-to-24-Week Changes in Biomarkers 
and FMD ....................................................................................................................................... 51 
Table 2.5 Sensitivity Analyses of Multivariate Linear Regression Models Examining the 
Association Between Changes in 0-to-12-Week Insomnia Symptoms and Changes in Biomarkers 
and FMD ....................................................................................................................................... 52 
 
 
 6 
LIST OF FIGURES 
Figure 2.1. Visual representation of the examined associations between 0-to-12-week changes in 
sleep disturbance and 0-to-12-week and 12-to-24-week changes in interleukin-6 (IL-6), C-
reactive protein (CRP), D-dimer, and brachial flow-mediated dilation (FMD). .......................... 53 
 
 
 7 
INSOMNIA SYMPTOMS AND BIOMARKERS OF MONOCYTE 
ACTIVATION, SYSTEMIC INFLAMMATION, AND COAGULATION IN 
HIV: VETERANS AGING COHORT STUDY 
Brittanny M. Polanka, MS1; Suman Kundu, DSc, MSc2; Kaku A. So-Armah, PhD3; Matthew S. 
Freiberg, MD, MSc2; Samir K. Gupta, MD4; Tamika C.B.  Zapolski, PhD1; Adam T. Hirsh, 
PhD1; Roger J. Bedimo, MD, MS5; Matthew J. Budoff, MD6; Adeel A. Butt, MD, MS7-9; Chung-
Chou H. Chang, PhD10; Stephen S. Gottlieb, MD11; Vincent C. Marconi, MD12-14; Julie A. 
Womack, PhD, CNM, FNP-BC15,16; Jesse C. Stewart, PhD1 
 
1Department of Psychology, Indiana University-Purdue University Indianapolis (IUPUI), 
Indianapolis, Indiana 
2Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University School of 
Medicine, Nashville, Tennessee 
3Division of General Internal Medicine, Boston University School of Medicine, Boston, 
Massachusetts 
4Division of Infectious Diseases, Department of Medicine, Indiana University School of 
Medicine, Indianapolis, Indiana 
5Division of Infectious Diseases, VA North Texas Healthcare System, Dallas, Texas 
6Los Angeles Biomedical Research Institute, Torrance, California 
7VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania 
8Weill Cornell Medical College, Doha, Qatar, and New York, New York 
9Hamad Medical Corp, Doha, Qatar 
10Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, 
Pennsylvania 
11Department of Medicine, University of Maryland School of Medicine and Baltimore VAMC, 
Baltimore, Maryland 
12Division of Infectious Diseases, Department of Medicine, Emory University School of 
Medicine, Atlanta, Georgia 
13Atlanta VA Medical Center, Atlanta, Georgia 
14Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, 
Georgia 
15VA Connecticut Healthcare System, West Haven, Connecticut 
16Yale University School of Nursing, West Haven, Connecticut 
Corresponding Author: Jesse C. Stewart, PhD, Department of Psychology, Indiana University-
Purdue University Indianapolis (IUPUI), 402 N. Blackford St., LD 100E, Indianapolis, IN 
46202. Telephone: (317) 274-6761. Fax: (317) 274-6756. Email address: jstew@iupui.edu 
Abstract 
Background: Insomnia may be a risk factor for cardiovascular disease in HIV (HIV-CVD); 
however, mechanisms have yet to be elucidated. Methods: We examined cross-sectional 
associations of insomnia symptoms with biological mechanisms of HIV-CVD (immune 
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activation, systemic inflammation, and coagulation) among 1,542 people living with HIV from 
the Veterans Aging Cohort Study (VACS) Biomarker Cohort. Past-month insomnia symptoms 
were assessed by the item, “Difficulty falling or staying asleep?,” with the following response 
options: “I do not have this symptom” or “I have this symptom and…” “it doesn’t bother me,” “it 
bothers me a little,” “it bothers me,” “it bothers me a lot.” Circulating levels of the monocyte 
activation marker soluble CD14 (sCD14), inflammatory marker interleukin-6 (IL-6), and 
coagulation marker D-dimer were determined from blood specimens. Demographic- and fully-
adjusted (CVD risk factors, potential confounders, HIV-related factors) regression models were 
constructed, with log-transformed biomarker variables as the outcomes. We present the 
exponentiated regression coefficient (exp[b]) and its 95% confidence interval (CI). Results: For 
sCD14 and D-dimer, we observed no significant associations. For IL-6, veterans in the “bothers 
a lot” group had 15% higher IL-6 than veterans in the “I do not have this symptom” group in the 
demographic-adjusted model (exp[b]=1.15, 95%CI=1.02-1.29, p=.03). This association was 
nonsignificant in the fully-adjusted model (exp[b]=1.07, 95%CI=0.95-1.19, p=.25). Conclusion: 
We observed little evidence of relationships between insomnia symptoms and markers of 
biological mechanisms of HIV-CVD. Other mechanisms may be responsible for the insomnia-
CVD relationship in HIV; however, future studies with comprehensive assessments of insomnia 
symptoms are warranted. 
Introduction 
 Although still below that of the general population, the expected lifespan of people living 
with human immunodeficiency virus (PLWH) has increased considerably with antiretroviral 
therapy (ART) (1). However, this increased lifespan has been accompanied by a rise in non-
communicable diseases – most notably cardiovascular disease (CVD), a leading cause of death in 
PLWH (2-4). In fact, PLWH are at nearly double the risk of CVD compared to those without 
HIV (5), and this elevated risk persists independent of the risk attributed to HIV, ART, and 
traditional and non-traditional CVD risk factors (6-8). Thus, there is a need to identify novel risk 
factors for CVD in HIV (HIV-CVD) with the potential to serve as future CVD primary 
prevention targets. 
 Insomnia is one such possible risk factor for CVD that has been largely ignored in the 
HIV population. Sleep disturbance is a commonly reported experience among PLWH, with an 
 9 
estimated prevalence of 58% (9). In addition, PLWH may exhibit an increased risk of developing 
sleep disturbance compared to the general population (10). Our recent work using the Veterans 
Aging Cohort Study (VACS) Survey Cohort was the first to examine insomnia as a predictor of 
HIV-CVD. We found that PLWH bothered a lot by difficulty falling or staying asleep exhibited a 
66% greater risk of incident CVD than those without these symptoms, independent of 
demographics, CVD risk factors, additional potential confounders, and HIV-specific factors (11). 
Insomnia has received greater attention as a possible CVD risk factor in the general 
population, with substantial evidence supporting an insomnia-CVD relationship. Meta-analytic 
evidence suggests that elevated insomnia symptoms are associated with an increased risk of 
CVD events (risk ratios [RRs] = 1.28-1.55) (12-14). Furthermore, insomnia has been associated 
with putative biological mechanisms of HIV-CVD (15), including altered immune function (16), 
increased systemic inflammation (17), and heightened coagulation (18-24) in non-HIV samples. 
Most striking are findings from the largest randomized control trial of behavioral interventions 
for insomnia in older adults suggesting a causal link between insomnia and CVD risk. 
Specifically, Irwin et al. (25) found that older adults receiving cognitive-behavioral therapy for 
insomnia (CBT-I), versus a sleep education seminar, exhibited a 74% lower risk of elevated C-
reactive protein (CRP; ≥ 3.0 mg/L), an inflammatory marker implicated in and predictive of the 
development of CVD (26), at the 16-month follow-up.   
 Given our previous work indicating a link between insomnia and incident CVD in PLWH 
and the complementary supportive evidence in the general population, it is now important to 
examine the relationships between insomnia and putative biological mechanisms of HIV-CVD. 
Thus, the aim of this study was to determine the associations of insomnia symptoms with 
biomarkers of immune activation, systemic inflammation, and coagulation among PLWH. We 
hypothesized that insomnia symptoms would be positively associated with circulating levels of 
the monocyte activation marker soluble CD14 (sCD14), the inflammatory marker interleukin-6 
(IL-6), and the coagulation marker D-dimer. 
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Methods 
Study design, setting, and participants 
Data for the present study came from the VACS Biomarker Cohort, a cross-sectional 
subsample of the VACS-9 parent study consisting of participants who provided a blood sample 
between 2005-2006 (27, 28). VACS-9 is a prospective, multisite, cohort study of HIV-positive 
veterans and age, sex, race/ethnicity, and clinical site-matched HIV-negative veterans from nine 
Department of Veterans Affairs (VA) medical centers across the U.S. (29, 30). From the total 
VACS Biomarker Cohort sample (N = 2,386), we excluded veterans without HIV (n = 837) and 
those missing a follow-up date (n = 7). Thus, our final sample consisted of 1,542 HIV-positive 
veterans (see Table 1.1 for participant characteristics). 
Measures and procedures 
Exposure variable. Insomnia symptoms were assessed by the insomnia item of the 
VACS HIV Symptom Index – a 20-item, self-report questionnaire assessing the frequency and 
bother of common symptoms in HIV-positive adults exposed to multidrug ART and protease 
inhibitors (31). The VACS HIV Symptom Index asks participants to indicate what response best 
describes their experience of each symptom over the past four weeks using the following 
options: 0 = “I do not have this symptom” or “I have this symptom and…” 1 = “it doesn’t bother 
me,” 2 = “it bothers me a little,” 3 = “it bothers me,” or 4 = “it bothers me a lot.” We used 
responses to the insomnia item – “Difficulty falling or staying asleep?” – to create a 5-level 
insomnia symptoms variable. From this variable, four dummy coded variables were created with 
the “No Difficulty Falling or Staying Asleep” group as the reference category (i.e., “I do not 
have this symptom”) (11). 
Outcome variables. Three outcomes were examined: the monocyte activation marker 
sCD14 (ng/mL), the inflammatory marker IL-6 (pg/mL), and the coagulation marker D-dimer 
(μg/mL). As is described elsewhere (27, 28, 32), participant blood samples were collected at one 
time point between 2005-2006. Serum samples were collected using serum separator and EDTA 
tubes and were shipped to a central repository at the Massachusetts Veterans Epidemiology 
Research and Information Center. Assays were performed at the University of Vermont’s 
Laboratory for Clinical Biochemistry Research. All biomarker measurements used four controls 
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per sample to assess interassay coefficients of variability (CVs). sCD14 was measured with an 
enzyme-linked immunsorbent assay (Quantikine sCD14 Immunoassay, R&D Systems, 
Minneapolis, MN) with a detectable range of 40-3,200 ng/mL; CVs ranged from 7.2-8.1%. IL-6 
was measured using a chemiluminescent immunoassay (QuantiGlo IL-6 immunoassay, R&D 
Systems, Minneapolis, MN) with a detectable range of 0.4-10,000 pg/mL; CVs ranged from 7.7-
12.3%. D-dimer was measured by a STAR automated coagulation analyzer (Diagnostica Stago) 
using an immunoturbidometric assay (Liatest D-DI; Diagnostica Stago, Parsippany, NJ) with a 
detectable range of 0.01-20 ug/mL; CVs ranged from 2.8-14.8%. Because of their positively 
skewed distributions, all three biomarkers were log-transformed to approximate normal 
distributions.  
Covariates. Similar to our previous work, all covariates were determined using self-
report measure data or routine clinical care data in the electronic medical record obtained closest 
to the blood collection date (27). The following covariates were included, given their prior 
associations with insomnia, HIV-CVD, or both. 
Demographic factors. Demographic factors were age, sex (male, female), and 
race/ethnicity (White, African American, Hispanic, Other).  
CVD risk factors. CVD risk factors were prevalent CVD, hypertension, diabetes, body 
mass index (BMI), smoking, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein 
(LDL) cholesterol, triglycerides, and statin use. Prevalent CVD was defined by the presence of a 
International Classification of Diseases, Ninth Revision (ICD-9) or a Current Procedural 
Terminology (CPT) code prior to the blood collection date for myocardial infarction, unstable 
angina, coronary heart disease, stroke, congestive heart failure, coronary artery bypass graft, or 
percutaneous coronary intervention. Hypertension was defined by the average of the three 
routine outpatient blood pressure values obtained closest to the blood collection date. We created 
two dummy variables to categorize hypertension based on Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure thresholds as no 
hypertension (blood pressure <140/90 mmHg and no antihypertensive medication [reference 
category]), controlled hypertension (<140/90 mmHg with antihypertensive medication), or 
uncontrolled hypertension (≥140/90 mmHg) (33). Diabetes (yes/no) was defined by a validated 
metric incorporating glucose measurements, diabetes medication use, and/or at least one 
inpatient or two outpatient ICD-9 codes for diabetes (34, 35). BMI (kg/m2) was defined by one 
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outpatient measurement collected during routine clinical care and was modeled continuously. 
Smoking (never [reference category], current, or former smoker) was determined from the VA 
Health Factors data, a system utilizing electronic medical record data (36). Measurements of the 
lipids (LDL cholesterol, HDL cholesterol, and triglycerides) were obtained from the VA 
Corporate Data Warehouse and modeled continuously. Statin use (yes/no) was defined as a filled 
prescription receipt for a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor at time of 
the blood collection.  
Additional potential confounders. Additional biomedical and behavioral potential 
confounders were hepatitis C infection, renal function, anemia, alcohol use, and cocaine use. 
Hepatitis C infection (yes/no) was defined by a positive hepatitis C virus antibody test or at least 
one inpatient or two outpatient ICD-9 codes for hepatitis C infection (37). Renal function was 
defined by estimated glomerular filtration rate (eGFR). Anemia was defined by hemoglobin. 
Both eGFR and hemoglobin were extracted from the VA Corporate Data Warehouse and 
modeled continuously. Alcohol use was determined by the Alcohol Use Disorders Identification 
Test (AUDIT-C) administered closest to the blood collection date and by the presence of alcohol 
abuse/dependence ICD-9 codes in the electronic medical record prior to the blood collection 
date. We combined these two data sources into one dichotomous variable as no current use or 
non-hazardous use versus hazardous use (AUDIT-C ≥ 4) or alcohol abuse/dependence disorder. 
Cocaine use was assessed by self-report and by the presence of cocaine use disorder ICD-9 codes 
in the electronic medical record prior to the blood collection date. We combined these two data 
sources into one dichotomous variable as never tried or no use in past year versus use in the past 
year or cocaine abuse/dependence disorder. 
HIV-related factors. The HIV-related factors were HIV-1 RNA level, CD4+ T cell count, 
and ART use. HIV-1 RNA level and CD4+ T-cell count, measured during routine outpatient 
visits, were determined from the VA Corporate Data Warehouse data obtained closest to the 
blood collection date and modeled continuously. ART use (yes/no) was defined as a filled 
prescription receipt for any ART closest to the blood collection date (-180 days to +7 days of 
date). 
Insomnia-related factors. The insomnia-related factors were depressive symptoms, non-
benzodiazepine sleep medication use, and antidepressant medication use. Given the overlap 
between insomnia and depression, depression symptoms were included in order to examine 
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insomnia’s independent associations with the biomarkers. Antidepressant medication use was 
included, as these medications are commonly prescribed for sleep disturbance (38, 39) and have 
been associated with systemic inflammation among PLWH (40). Depressive symptoms were 
measured by the Patient Health Questionnaire-9 (PHQ-9). We removed item 3 (“Trouble falling 
or staying asleep, or sleeping too much”) from the PHQ-9 total score calculation and 
subsequently refer to it as PHQ-9 (no sleep item). Non-benzodiazepine sleep medication use 
(yes/no) was defined as a filled prescription receipt closest to the blood collection date (-ever to 
+180 days of date) for the following medications: zolpidem, zaleplon, eszopiclone, and indiplon. 
Antidepressant medication use was defined as a filled prescription receipt for an antidepressant 
medication closest to the blood collection date (-ever to +180 days of date). We computed three 
dichotomous variables (yes/no) based on the antidepressant medication type – serotonin reuptake 
inhibitor (SSRI), tricyclic antidepressant (TCA), and miscellaneous other antidepressant. Of 
note, the treatment indications for non-benzodiazepine and antidepressant medications are not 
known.  
Statistical analysis 
Descriptive statistics – i.e., median (first quartile, third quartile) and frequency count (%) 
– for the participant characteristics and the biomarker levels across insomnia symptom categories 
were computed. 
Multivariate linear regression models were constructed to estimate the associations 
between insomnia symptoms and monocyte activation, inflammatory, and coagulation markers in 
HIV-positive veterans. Two models were constructed for each outcome variable (log-
transformed sCD14, IL-6, and D-dimer). Model 1 (demographics-adjusted) consisted of the four 
insomnia symptom dummy coded variables, age, sex, and race/ethnicity. Model 2 (fully-
adjusted), which was our primary model, included the Model 1 variables plus the CVD risk 
factors (prevalent CVD, hypertension, diabetes, BMI, smoking, LDL cholesterol, HDL 
cholesterol, triglycerides, and statin use), the additional potential confounders (hepatitis C 
infection, renal function [eGFR], anemia [hemoglobin], alcohol use, and cocaine use), and the 
HIV-related factors (HIV-1 RNA level, CD4+ T cell count, and ART use). Due to the use of log-
transformed outcome variables, we present the exponentiated regression coefficient [exp(b)] and 
its 95% confidence interval (CI) for each association of interest. We interpret the percent change 
 14 
in each biomarker per 1-unit increase in the insomnia symptoms dummy coded variables (i.e., 
switching from the reference category “No Difficulty Falling or Staying Asleep” to the 
respective insomnia symptom category) using the following equation: [exp(b)-1] x 100.  
Three sensitivity analyses were conducted to individually examine the potential influence 
of the insomnia-related variables on the associations of interest. These three models were 
constructed for each outcome variable as follows: Model 3: Model 2 plus PHQ-9 total score (no 
sleep item), Model 4: Model 2 plus non-benzodiazepine sleep medication use, and Model 5: 
Model 2 plus antidepressant medication use (SSRI, TCA, and miscellaneous other use). 
All analyses were performed using R software (version 3.5.2; www.r-project.org). To 
address missingness, data examine in regression models underwent multiple imputations using 
chained equations (MICE) with five separate imputed datasets generated based on predictive 
mean matching using the ‘mice’ library of R programming language. Regression models were fit 
in each imputed dataset and finally combined to obtain pooled effect sizes and standard errors 
using Rubin’s rule (41).  
Results 
Participant characteristics 
The characteristics of participants are presented in Table 1.1. The median age of our 
sample of 1,542 HIV-positive veterans was 52 years, with the majority being male (97%) and 
African American (69%). Participants exhibited high CVD risk factor burden, particularly for 
hypertension (72%) and current smoking (50%). Our sample had a high prevalence of hepatitis C 
co-infection at 47%, well above the predicted estimate in the general population of PLWH at 
2.4% (42). Also of note, our sample had a high prevalence of substance misuse/abuse (42% and 
21% for alcohol and cocaine, respectively). Regarding insomnia-related variables, participants 
exhibited lower use of non-benzodiazepine medications (10%) but higher use of antidepressant 
medications (26-43%), with a median PHQ-9 (no sleep item) score of 3.0. The distribution of 
participants across the insomnia symptom categories is presented in Table 1.2, with each 
category’s respective original unit median (first quartile, third quartile) for sCD14, IL-6, and D-
dimer. Visual inspection of Table 1.2 suggests a large proportion of participants denied having 
insomnia symptoms (40%), with the remaining participants distributed relatively evenly across 
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the other insomnia symptom categories. Approximately 50% of our sample endorsed some level 
of bother with insomnia symptoms.   
Insomnia symptoms and sCD14 
As is shown in Table 1.3, the dummy coded variables comparing “Doesn’t Bother,” 
“Bothers a Little,” “Bothers,” and “Bothers a Lot” categories to the “No Difficulty Falling or 
Staying Asleep” reference category were not significant in Model 1 (demographic-adjusted; p-
value range: 0.09-0.53) or Model 2 (fully-adjusted; p-value range: 0.13-0.93). Results remained 
consistent in the sensitivity analyses individually adjusting for PHQ-9 (no sleep item; Model 3), 
non-benzodiazepine sleep medication use (Model 4), or antidepressant medication use (Model 
5). 
Insomnia symptoms and IL-6 
 The dummy coded variables comparing “Doesn’t Bother,” “Bothers a Little,” and 
“Bothers” categories to the “No Difficulty Falling or Staying Asleep” reference category were 
not significant in Model 1 (p-value range: 0.28-1.00) or Model 2 (p-value range: 0.19-0.89; see 
Table 1.3). In contrast, the dummy coded variable comparing the “Bothers a Lot” category to the 
“No Difficulty Falling or Staying Asleep” reference category was significant in Model 1 (exp[b] 
= 1.15, 95% CI: 1.02-1.29, p = 0.03) adjusting for demographic factors. The exp(b) of 1.15 
indicates that a 1-unit change in insomnia symptoms category (i.e., moving from “No Difficulty 
Falling or Staying Asleep” to “Bothers a Lot”) was associated with a 15% increase in IL-6 on 
average [(1.15 – 1) x 100] while controlling for demographic factors. However, this association 
was attenuated and not significant in Model 2 (exp[b] = 1.07, 95%CI: 0.95-1.19, p = 0.25) 
adjusting for additional potential confounders. Results remained consistent with those of Model 
2 in the sensitivity analyses individually adjusting for the insomnia-related factors (Models 3-5).  
Insomnia symptoms and D-dimer 
For Models 1 and 2, all of the insomnia symptom dummy coded variables were not 
significant in Model 1 (p-value range: 0.18-0.91) or Model 2 (p-value range: 0.34-0.75; see 
Table 1.3). Results remained consistent in the sensitivity analyses (Models 3-5). 
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Discussion 
 Our examination of the VACS Biomarker Cohort data did not support our hypotheses 
that greater insomnia symptoms would be associated with higher circulating levels of markers of 
monocyte activation, systemic inflammation, and coagulation in PLWH. All but one of the tested 
associations between insomnia symptom categories and sCD14, IL-6, and D-dimer were not 
significant. Furthermore, the one significant association observed in a demographics-adjusted 
model – i.e., higher IL-6 among veterans bothered a lot by difficulty falling or staying asleep – 
was no longer significant in our primary model further adjusting for CVD risk factors, additional 
potential confounders, and HIV-related factors. Taken together, the present results suggest that 
insomnia symptoms may not be associated with the putative biological mechanisms of HIV-
CVD examined in the present study.  
 To our knowledge, this is the first study to investigate associations between insomnia 
symptoms and immune activation or coagulation markers among PLWH. Others have examined 
the relationship between sleep parameters or sleep disturbance and systemic inflammation, 
reporting mixed results. Of the four available studies, two examined group differences, one using 
self-reported sleep onset latency (SOL)  30 or > 30 minutes (43) and one using objectively 
measured SOL, wake-after-sleep-onset (WASO), time of sleep onset, total sleep time (TST), and 
sleep efficiency (SE) split at the sample median for each variable (44). Tests of group differences 
between these two studies yielded conflicting results. Gay et al. (43) found no group differences 
in various inflammatory markers (i.e., CRP, IL-1beta, IL-2, IL-6, IL-10, IL-13, and tumor 
necrosis factor [TNF]-alpha) between those with SOL  30 and > 30 minutes. Wirth et al. (44) 
found significantly higher or trending higher CRP and IL-6 among those with indicators of 
poorer sleep quantity and quality (i.e., lower TST, later sleep onset time, lower SE, higher SOL, 
and higher WASO). In addition, three of the four studies examined linear or correlational 
associations. Gay et al. (43) observed significant or trending positive associations between IL-13 
and SOL > 30 minutes (a 1-SD increase in IL-13 was associated with a 34% increased odds of 
SOL > 30 minutes, p = .024) and IL-10 (a 1-SD increase in IL-10 was associated with a 27% 
increased odds of SOL > 30 minutes, p = .068), controlling for genomic estimates of ancestry, 
race/ethnicity, and viral load. SOL > 30 minutes was not associated with IL-1beta, IL-2, IL-6, 
TNF-alpha, and CRP. Lee et al. (45) observed positive correlations between objectively 
measured WASO and CRP (rho = .135, p = .023) and TNF-alpha (rho = .121, p = .042), a 
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trending negative association between WASO and IL-13 (rho = -.111, p = .061), and null 
associations between WASO and IL-1beta, IL-2, IL-6, and IL-10. Moore et al. (46) observed 
negative correlations between self-reported sleep disturbance and TNF-gamma (rho = -.697, p = 
.017) and TNF-alpha (rho = -.697, p = .017) but not for IL-6 among women, with no significant 
associations observed among men. Differences in results between the four available studies and 
our own may be due to differences in the definition of the sleep disturbance variables (e.g., 
subjective versus objective measurement) and/or sample characteristics (e.g., percentage with 
undetectable versus detectable viral loads, veteran versus non-veteran). Of note, because Gay et 
al. (43) and Lee et al. (45) utilized similar samples from The Symptoms and Genetic Study, our 
current knowledge of the insomnia-inflammation relationship, including the present study, is 
based on only four samples of PLWH. 
The lack of associations between insomnia and putative biological mechanisms of HIV-
CVD in the present study raises two possibilities. The first possibility is our null results reflect 
the state of nature. If accurate, this would suggest that other mechanisms underlie the previously 
observed insomnia-CVD relationship among PLWH. Other potential mechanisms include 
hypertension and overweight/obesity, which consist of both biological and behavioral 
components. Regarding hypertension, meta-analytic evidence in the general population suggests 
that adults with individual symptoms of insomnia have a 14-21% increased risk of hypertension 
(47). To our knowledge, there are no published studies examining longitudinal associations 
between sleep variables and hypertension or blood pressure among PLWH. Elucidating 
insomnia’s role in hypertension in the HIV population could be of great importance, given 
hypertension’s high prevalence (19-52%) and its ties to pathological consequences of the HIV 
virus (e.g., chronic inflammation) and ART treatment (e.g., mitochondrial toxicity and insulin 
resistance) (48). Concerning overweight/obesity, general population data suggests that sleep 
restriction is positively related to subjective hunger, caloric intake, and weight gain and 
negatively related to insulin sensitivity (49). A few existing studies have observed a positive 
association between sleep disturbance and weight variables among PLWH (i.e., obesity and 
increased waist size) (50, 51), although it has not been a focus of the HIV literature thus far. 
Other potential behavioral mechanisms identified in the general population that may translate to 
the HIV population includes decreased physical activity (52), smoking (53), and poor diet (54).    
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The second possibility is our null results are due to methodological factors and may or 
may not reflect the state of nature. For instance, our assessment of insomnia relied on a single 
item that assessed only difficulty falling or staying asleep within the past four weeks, missing 
symptoms such as early morning awakening, insomnia-related impairment and/or distress, and 
insomnia symptom frequency and duration. This reduced content validity could contribute to the 
misclassification of cases (e.g., participants experiencing symptoms of insomnia are 
inappropriately classified as not experiencing insomnia). Future research endeavors on insomnia 
in the HIV population should consider incorporating comprehensive and validated assessments 
of insomnia symptoms and/or insomnia disorder. To assess insomnia symptoms, we recommend 
the Insomnia Severity Index (ISI), which is sensitive to treatment response and can be 
administered online (55, 56). To assess insomnia disorder, we recommend either the Structured 
Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition 
(DSM-5) Sleep Disorders (SCISD) interview (57) or the Diagnostic Interview for Sleep Patterns 
and Disorders (DISP) based on The International Classification of Sleep Disorders, second 
edition (ICSD-2) criteria (58).  
 In addition to our study's strengths (large sample, extensive adjustment for potential 
confounders, and inclusion of monocyte activation and coagulation biomarkers), there are 
important limitations worth considering. First, the cross-sectional, observational study design 
prevents examination of the directionality of associations between insomnia symptoms and 
putative biological mechanisms of HIV-CVD. It is plausible that immune activation and/or 
systemic inflammation may predict insomnia symptoms among PLWH, although human 
research examining this direction is limited (59). Second, as previously mentioned, our insomnia 
variable was limited to a single item and did not comprehensively capture insomnia symptoms. 
Third, the examined biomarkers may not adequately capture the intricate and interconnected 
nature of the immune and coagulation processes involved in the development of HIV-CVD. 
However, the three biomarkers examined are among the most studied in relation to CVD risk 
(60), increasing our ability to make comparisons with past studies. Fourth, we were unable to 
adjust for some factors that may confound the relationship between insomnia symptoms and 
putative biological mechanisms of HIV-CVD (e.g., physical inactivity, obstructive sleep apnea). 
Fifth, although not inherently a limitation, the present study examined a predominantly male and 
entirely veteran sample. This may reduce the generalizability of our results to other demographic 
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groups, such as women and non-veterans. Future studies examining the mechanisms underlying 
the insomnia-CVD relationship among PLWH should ideally utilize a prospective design with a 
comprehensive assessment of insomnia (e.g., ISI, SCISD, DISP); multiple indicators of immune 
activation, systemic inflammation, and coagulation; and more inclusive samples of PLWH.  
 In summary, we did not observe significant associations between insomnia symptoms and 
markers of immune activation, systemic inflammation, or coagulation. Our results raise the 
possibility that other mechanisms (e.g., hypertension or overweight/obesity) may be responsible 
for observed associations between insomnia symptoms and incident HIV-CVD. However, further 
research into the insomnia-biological mechanism relationships is still warranted as our study, and 
others in the extant literature, did not comprehensively assess insomnia. Ultimately, elucidating 
mechanistic pathways of the insomnia-CVD relationship in people with HIV could determine the 
viability of insomnia as a potential behavioral treatment target for the management of chronic 
immune activation and the subsequent risk of CVD among PLWH. 
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Table 1.1  
Characteristics of Veterans with HIV in the VACS Biomarker Cohort (N = 1,542) 
Demographic Factors  
  Age, years 52.1 [46.8, 57.5] 
  Sex, male 1,500 (97) 
  Race/Ethnicity  
White 292 (19) 
African American 1,065 (69) 
Hispanic 127 (8) 
Other 58 (4) 
CVD Risk Factors  
  Prevalent CVD 269 (17) 
  Hypertension  
None 438 (28) 
Controlled 748 (49) 
Uncontrolled 355 (23) 
  Diabetes 290 (19) 
  BMI, kg/m2 25.2 [22.7, 28.3] 
  Smoking  
Never 370 (24) 
Current 772 (50) 
Former 398 (26) 
  LDL Cholesterol, mg/dL 97.3 [75.0, 122.0] 
  HDL Cholesterol, mg/dL 42.0 [33.0, 52.0] 
  Triglycerides, mg/dL 140.0 [90.0, 209.0] 
  Statin Use 463 (30) 
Additional Potential Confounders  
  Hepatitis C Infection 724 (47) 
  eGFR, mL/min/1.73m2 95.7 [79.8, 114.1] 
  Hemoglobin, g/dL 14.0 [12.9, 15.0] 
  Alcohol Use, hazardous use or 
abuse/dependence 
653 (42) 
  Cocaine Use, past-year use or 
abuse/dependence 
324 (21) 
Insomnia-Related Factors  
  PHQ-9 (no sleep item) 3.0 [0.0, 9.0] 
  Non-benzodiazepine Sleep Medication Use 146 (10) 
  Antidepressant Medication Use  
SSRI Use 665 (43) 
TCA Use 393 (26) 
Miscellaneous Other Use 652 (42) 
HIV-Related Factors  
  HIV-1 RNA Level, copies/mL 75.0 [50.0, 3634.0] 
  CD4+ T Cell Count, mm3 399.0 [250.0, 586.3] 
  ART regimen 1,302 (84) 
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Table 1.1 Continued 
Outcome Variables  
  sCD14, ng/mL 1,719 [1,448, 2,085] 
  IL-6, pg/mL 2.08 [1.42, 3.38] 
  D-dimer, μg/mL 0.26 [0.15, 0.49] 
Note. Continuous variables are presented as median [first quartile, third quartile]. Outcome 
variables are presented in their original, untransformed units. Categorical variables are presented 
as n (%).  
The following variables include fewer than 1,542 participants because of missing data (n, % 
missing): hypertension (3, 0.2%), BMI (5, 0.3%), smoking (2, 0.1%), LDL cholesterol (42, 2.7%), 
HDL cholesterol (39, 2.5%), triglycerides (17, 1.1%), eGFR (1, 0.1%), hemoglobin (1, 0.1%), 
alcohol use (5, 0.3%), cocaine use (76, 4.9%), PHQ-9 (79, 5.1%), HIV-1 RNA (2, 0.1%), and 
CD4+ cell count (2, 0.1%). 
HIV = human immunodeficiency virus; VACS = Veterans Aging Cohort Study; CVD = 
cardiovascular disease; BMI = body mass index; LDL = low-density lipoprotein; HDL = high-
density lipoprotein; eGFR = estimated glomerular filtration rate; PHQ-9 = Patient Health 
Questionnaire-9; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant; 
ART = antiretroviral therapy; sCD14 = soluble CD14; IL-6 = interleukin-6. 
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Table 1.2  
Biomarker Levels across Insomnia Symptom Categories of Veterans with HIV in the VACS 
Biomarker Cohort 
Insomnia Symptoms 
sCD14 
(ng/mL) 
IL-6 
(pg/mL) 
D-dimer 
(μg/mL) 
No Difficulty Falling or 
Staying Asleep (n = 611) 
1678.78 [1408.06, 
2101.91] 
2.01 [1.37, 3.34] 0.28 [0.16, 0.49] 
Doesn’t Bother (n = 147) 
1746.91 [1480.16, 
2193.70] 
2.08 [1.43, 3.58] 0.26 [0.16, 0.50] 
Bothers a Little (n = 330) 
1731.93 [1446.65, 
2061.89] 
1.98 [1.39, 3.20] 0.26 [0.15, 0.47] 
Bothers (n = 217) 
1750.63 [1492.02, 
2029.61] 
2.14 [1.55, 3.42] 0.29 [0.16, 0.51] 
Bothers a Lot (n = 211) 
1728.03 [1492.17, 
2039.50] 
2.40 [1.54, 3.62] 0.28 [0.18, 0.49] 
Note. Outcome variables are presented as median [first quartile, third quartile] in their original units. A total 
of 26 cases are not included in Table 2, as they were imputed due to missing data on the insomnia symptoms 
item of the VACS HIV Symptom Index. 
HIV = human immunodeficiency virus; VACS = Veterans Aging Cohort Study; sCD14 = soluble CD14; IL-
6 = interleukin-6. 
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Table 1.3  
Associations of Insomnia Symptoms Categories with sCD14, IL-6, and D-dimer levels in Veterans with HIV in the VACS Biomarker Cohort (N = 
1,542) 
Model 
sCD14 IL-6 D-dimer 
exp(b) 95%CI 
p-
value 
exp(b) 95%CI 
p-
value 
exp(b) 95%CI 
p-
value 
Model 1: Demographic-adjusted          
No Difficulty Falling or Staying Asleep Ref. --- --- Ref. --- --- Ref. --- --- 
Doesn’t Bother 1.05 (0.99-1.10) 0.09 1.00 (0.87-1.15) 1.00 1.07 (0.89-1.28) 0.48 
Bothers a Little 1.02 (0.98-1.06) 0.38 0.98 (0.89-1.09) 0.73 1.01 (0.88-1.15) 0.91 
Bothers 1.02 (0.98-1.07) 0.31 1.07 (0.95-1.21) 0.28 1.10 (0.94-1.29) 0.22 
Bothers a Lot 1.01 (0.97-1.06) 0.53 1.15* (1.02-1.29) 0.03 1.11 (0.95-1.30) 0.18 
Model 2: Fully-adjusted          
No Difficulty Falling or Staying Asleep Ref. --- --- Ref. --- --- Ref. --- --- 
Doesn’t Bother 1.04 (0.99-1.09) 0.13 0.99 (0.87-1.13) 0.87 1.06 (0.90-1.26) 0.49 
Bothers a Little 1.00 (0.96-1.03) 0.93 0.94 (0.85-1.03) 0.19 0.98 (0.86-1.11) 0.75 
Bothers 1.00 (0.96-1.05) 0.85 1.01 (0.90-1.14) 0.89 1.08 (0.92-1.26) 0.34 
Bothers a Lot 1.01 (0.97-1.05) 0.70 1.07 (0.95-1.19) 0.25 1.06 (0.91-1.23) 0.47 
Model 3: PHQ-9 (no sleep item)          
No Difficulty Falling or Staying Asleep Ref. --- --- Ref. --- --- Ref. --- --- 
Doesn’t Bother 1.04 (0.99-1.09) 0.15 1.00 (0.88-1.14) 0.97 1.05 (0.89-1.25) 0.55 
Bothers a Little 1.00 (0.96-1.03) 0.85 0.95 (0.86-1.04) 0.28 0.97 (0.85-1.10) 0.65 
Bothers 1.00 (0.96-1.05) 0.97 1.03 (0.91-1.16) 0.68 1.06 (0.90-1.25) 0.47 
Bothers a Lot 1.00 (0.96-1.05) 0.86 1.09 (0.97-1.23) 0.16 1.03 (0.88-1.22) 0.68 
Model 4: Non-Benzodiazepine Sleep 
Medication Use 
  
 
      
No Difficulty Falling or Staying Asleep Ref. --- --- Ref. --- --- Ref. --- --- 
Doesn’t Bother 1.04 (0.99-1.09) 0.13 0.99 (0.87-1.13) 0.88 1.06 (0.90-1.26) 0.49 
Bothers a Little 1.00 (0.96-1.03) 0.92 0.94 (0.85-1.03) 0.20 0.98 (0.86-1.11) 0.75 
Bothers 1.00 (0.96-1.05) 0.85 1.01 0.90-1.14 0.87 1.08 (0.92-1.26) 0.34 
Bothers a Lot 1.01 (0.96-1.05) 0.71 1.07 0.96-1.20 0.23 1.06 (0.91-1.23) 0.46 
Model 5: Antidepressant Medication Use          
No Difficulty Falling or Staying Asleep Ref. --- --- Ref. --- --- Ref. --- --- 
Doesn’t Bother 1.04 (0.99-1.09) 0.13 0.99 (0.87-1.13) 0.91 1.05 (0.89-1.25) 0.55 
Bothers a Little 1.00 (0.96-1.03) 0.87 0.94 (0.85-1.03) 0.20 0.96 (0.85-1.09) 0.54 
Bothers 1.00 (0.96-1.05) 0.98 1.00 (0.89-1.13) 0.96 1.05 (0.90-1.23) 0.53 
Bothers a Lot 1.01 (0.96-1.05) 0.75 1.07 (0.96-1.21) 0.23 1.01 (0.87-1.19) 0.86 
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Table 1.3 Continued 
Note. For the results presented in Table 3, the outcome variables are log-transformed. 
Model 1: Demographic-adjusted (age, sex, race/ethnicity) 
Model 2: Fully-adjusted (Model 1 + CVD Risk Factors: prevalent CVD, hypertension, diabetes, BMI, smoking, total cholesterol, statin use; Additional 
Potential Confounders: hepatitis C infection, renal function, anemia, alcohol use, cocaine use; HIV-Related Factors: HIV-1 RNA viral load, CD4+ T cell 
count, ART regimen) 
Model 3: PHQ-9 Total Score-adjusted (Model 2 + PHQ-9 [no sleep item]) 
Model 4: Non-Benzodiazepine Sleep Medication Use (Model 2 + non-benzodiazepine sleep medication use) 
Model 5: Antidepressant Medication Use (Model 4 + SSRI use, TCA use, and miscellaneous other antidepressant use) 
*p < 0.05 
sCD14 = soluble CD14; IL-6 = interleukin-6; HIV = human immunodeficiency virus; VACS = Veterans Aging Cohort Study; PHQ-9 = Patient Health 
Questionnaire-9; CVD = cardiovascular disease; BMI = body mass index; ART = antiretroviral therapy; SSRI = serotonin selective reuptake inhibitor; TCA 
= tricyclic antidepressant; Ref. = reference category 
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Abstract 
Background: While insomnia has been identified as a potential risk factor for cardiovascular 
disease in HIV (HIV-CVD), research on the underlying pathophysiological mechanisms is 
scarce. Methods: We examined associations between 0-to-12-week changes in sleep disturbance 
and the concurrent 0-to-12-week changes and the subsequent 12-to-24-week changes in markers 
of systemic inflammation, coagulation, and endothelial dysfunction among people living with 
HIV (n = 33-38) enrolled in a depression clinical trial. Sleep disturbance was measured using the 
Pittsburgh Sleep Quality Index. Inflammatory markers interleukin-6 (IL-6) and C-reactive 
protein (CRP) and coagulation marker D-dimer were determined from blood specimens; 
endothelial dysfunction marker brachial flow-mediated dilation (FMD) was determined by 
ultrasound. 0-to-12-week variables were calculated as 12-week visit minus baseline, and 12-to-
24-week variables were calculated as 24-week minus 12-week. We constructed multivariate 
linear regression models for each outcome adjusting for age, sex, race/ethnicity, Framingham 
risk score, and baseline depressive symptoms. Results: We did not observe statistically 
significant associations between 0-to-12-week changes in sleep disturbance and 0-to-12-week or 
12-to-24-week changes in IL-6, CRP, D-dimer, or FMD. However, we did observe potentially 
meaningful associations, likely undetected due to low power. For 0-to-12-weeks, every 1-
standard deviation (SD) increase, or worsening, in the sleep disturbance change score was 
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associated with a 0.41 pg/mL and 80 ng/mL decease in IL-6 and D-dimer, respectively. For 12-
to-24-weeks, every 1-SD increase in sleep disturbance change score was associated with a 0.63 
mg/L, 111 ng/mL, and 0.82% increase in CRP, D-dimer, and FMD, respectively. Conclusion: 
We observed potentially meaningful, though not statistically significant, associations between 
changes in sleep disturbance and changes in biological mechanisms underlying HIV-CVD over 
time. Some associations were in the expected direction, but others were not. Additional studies 
are needed that utilize larger samples and validated, comprehensive assessments of insomnia. 
Introduction 
 With the reduction in human immunodeficiency virus (HIV)/acquired immunodeficiency 
syndrome (AIDS)-related mortality due to effective antiretroviral therapy (ART), the HIV 
population is now facing new health challenges. One such challenge is that of sleep disturbance, 
including insomnia, among people living with HIV (PLWH). The HIV population has a high 
prevalence of self-reported sleep disturbance at 58% (1) and may have a higher risk of 
developing sleep disturbance than the general population or other immunocompromised groups 
(i.e., cancer patients) (2). When compared to other symptoms experienced by PLWH, sleep 
disturbance and its consequences (e.g., fatigue) are among the most commonly reported 
distressing symptoms (3). 
 Sleep disturbance has been associated with both general and HIV-specific factors in 
PLWH. Regarding general factors, sleep disturbance has been linked to psychological symptoms 
(e.g., depression, anxiety, and fatigue), substance use, pain, and cognitive impairment (4-8). 
Interestingly, the opposite relationship between sleep disturbance and age emerges among 
PLWH. While subjective sleep disturbance is positively associated with age in the general 
population (9), it is negatively associated with age in PLWH, as younger (i.e., 18-44 years) 
versus older (i.e., 45-80 years) adults exhibit higher rates of sleep disturbance (10). Regarding 
HIV-specific factors, sleep disturbance has been linked to advanced HIV disease/AIDS, longer 
duration of HIV infection, and particular ART regimens (e.g., efavirenz) (4). Research is mixed 
on whether or not poorly managed HIV (i.e., high viral load and/or low CD4 count) is related to 
sleep disturbance outside the context of advanced HIV disease/AIDS.  
 Sleep disturbance is of particular importance, given its potential association with another 
medical challenge being faced by the HIV population – namely, cardiovascular disease (CVD). 
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PLWH are over twice as likely to develop CVD than those without HIV (11). The increased risk 
of CVD in HIV (HIV-CVD) has been attributed to a several factors, including HIV infection, 
ART treatment, and an increased prevalence of traditional and non-traditional CVD risk factors 
(12, 13). However, the increased CVD risk in PLWH persists among those with optimal CVD 
risk profiles (14), suggesting the need to identify novel contributors to HIV-CVD. Sleep 
disturbance may be one such novel risk factor for HIV-CVD, given that insomnia symptoms 
have been associated with incident CVD in both general population (15-17) and HIV population 
(18) research. 
The putative biological mechanisms underlying HIV-CVD include systemic 
inflammation, altered coagulation, and endothelial dysfunction (19, 20). HIV population research 
has only recently begun to examine potential relationships between sleep disturbance and 
biological mechanisms of HIV-CVD. Specifically, the cross-sectional literature examining 
associations between sleep disturbance or objective sleep parameters and inflammatory markers 
among PLWH is small in size and has yielded mixed results (21-24). To our knowledge, no 
longitudinal studies of the sleep disturbance-inflammation relationship exist, nor do studies 
examining the sleep disturbance-coagulation or sleep disturbance-endothelial function 
relationships in PLWH. Thus, the purpose of the present study is to examine associations 
between changes in sleep disturbance and changes in inflammatory, coagulation, and endothelial 
dysfunction markers over time among PLWH. 
Methods 
Study design, setting, and participants 
 We utilized data from a 24-week randomized controlled pilot trial comparing 
computerized cognitive-behavioral therapy (CBT) for depression to usual care. HIV-positive, 
ART-treated, virologically suppressed adults with a positive depression screen were randomized 
in a 1:1 fashion. Following a screening visit, participants completed two entry visits (1-15 days 
apart), a 12-week follow-up visit, and a 24-week follow-up visit. Participants completed a blood 
draw and an ultrasound assessment of brachial artery flow-mediated dilation (FMD) at each visit 
and self-report questionnaires at the second entry, 12-week, and 24-week follow-up visits. 
Participants were required to fast and abstain from smoking for at least 8 hours prior to each 
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study visit. Randomization was completed at the second entry visit using a computerized 
algorithm stratified by baseline antidepressant use (yes/no).  
 Briefly, participants randomized to the intervention arm received an internet CBT 
program, Beating the Blues USTM (BtB), to be completed between the second entry and 12-week 
follow-up visits at a location of their choosing (e.g., at home or at one of the investigator's 
laboratory). BtB is an 8-session, online, stand-alone depression treatment program (see 
http://www.beatingthebluesus.com/ for video tutorial). BtB is empirically supported, with effect 
sizes similar to face-to-face CBT for depression (25-27). Participants randomized to the usual 
care arm were informed of their positive depression screen and were encouraged to follow-up 
with their primary care or HIV provider regarding their depression. In addition, providers of 
participants were sent a letter indicating their patient had screened positive for depression and 
was randomized to usual care; this letter also included a list of local mental health services.  
Participants were recruited from the HIV clinics of the Indiana University Medical Center 
and Eskenazi Health. At the screening visit, participants were screened for the following 
inclusion criteria: HIV-positive, at least 18 years of age, receipt of ART for at least 1 year prior 
to screening, HIV-1 RNA viral load of < 75 copies/mL, and a Patient Health Quesionnaire-9 
(PHQ-9) score of  10 (i.e., a clinically significant level of depressive symptoms) (28). 
Participants were also screened for the following exclusion criteria: active suicidality; history of 
psychotic or bipolar disorders based on chart review; pre-existing cardiovascular or 
inflammatory disease (with the exception of hepatitis B or C co-infection); treatment of 
malignancy in the last 6 months; elevated blood pressure (> 160/110 mmHg), fasting blood 
glucose or hemoglobin A1c (≥ 140 mg/dL or > 8.0%), or total cholesterol (> 240 mg/dL); 
reduced estimated glomerular filtration rate (< 50 mL/min/1.73m2); or current pregnancy or 
breastfeeding during the study period. Participants were allowed to engage in other depression 
treatments while enrolled in the study. 
Missing data across the blood-based biomarkers was among the same participants, while 
the missing data for FMD was among different participants than those with missing biomarker 
data. Thus, to maximize our sample size, we applied different exclusions to the study sample 
depending on the outcome (biomarkers versus FMD) and timeframe (0-to-12 weeks versus 12-
to-24 weeks) creating 4 separate analytic cohorts. For the 0-to-12-week biomarker analyses, from 
the total pilot trial sample (N = 54), we excluded participants who did not attend both study visits 
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(n = 4), were missing data on the exposure variable (n = 9) or outcome variables (n = 3), or were 
suspected of an infection producing drastic changes in biomarker levels over time (n = 1), 
resulting in a sample of 38 PLWH. For the 0-to-12-week FMD analysis, we excluded 
participants who did not attend both study visits (n = 4), were missing data on the exposure 
variable (n = 9) or outcome variable (n = 2), or were suspected of an infection producing drastic 
changes in biomarker levels over time (n = 1), resulting in a sample of 37 PLWH. For the 12-to-
24-week biomarker analyses, we excluded participants who did not attend both study visits (n = 
5), were missing data on the exposure variable (n = 9) or outcome variables (n = 6), or were 
suspected of an infection producing drastic changes in biomarker levels over time (n = 1), 
resulting in a sample of 33 PLWH. For the 12-to-24-week FMD analysis, we excluded 
participants who did not attend both study visits (n = 5), were missing data on the exposure 
variable (n = 9) or outcome variable (n = 6), or were suspected of an infection producing drastic 
changes in biomarker levels over time (n = 1), resulting in a sample of 33 PLWH.  
The study was conducted in accordance with the Helsinki Declaration, approved by the 
Indiana University Institutional Review Board, and registered with ClinicalTrials.gov 
(NCT02309372). 
Measures and procedures 
Exposure variable. Sleep disturbance was measured at the second entry, 12-week 
follow-up, and 24-week follow-up visits using the Pittsburgh Sleep Quality Index (PSQI). The 
PSQI is a 19-item self-report scale with research supporting its reliability and validity (29, 30). 
Meta-analytic evidence supports the PSQI’s specificity in assessing insomnia versus sleep-
disordered breathing, with strong associations observed with the Insomnia Severity Index (r = 
0.80) and sleep efficiency scores from sleep diaries (r = -0.76) and weak associations observed 
with the Apnea Hypopnea Index (r = 0.11-0.30) and number of oxygen desaturation events (r = 
0.21) (31). The PSQI measures sleep disturbance across seven components – sleep quality, sleep 
latency, sleep duration, habitual sleep efficiency, sleep disturbance, use of sleeping medications, 
and daytime dysfunction – with component scores ranging from 0-3. The seven component 
scores are summed to compute a global score ranging from 0-21. The 0-to-12-week sleep 
disturbance change score was calculated as 12-week minus second entry. This change score 
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reflects treatment phase changes in sleep disturbance, with more negative values indicating 
greater improvement. 
Outcome variables. Circulating levels of inflammatory markers interleukin-6 (IL-6) and 
C-reactive protein (CRP) and coagulation marker D-dimer were assessed at each study visit via 
blood draw. IL-6, CRP, and D-dimer were measured by standard enzyme-linked immunosorbent 
assay (ELISA) kits per instructions provided by the manufacturer (IL-6 and CRP: R&D Systems; 
D-dimer: Thermo Scientific). Assays were performed by the Center for Diabetes and Metabolic 
Diseases Translational Core at the Indiana University School of Medicine. In accordance with 
guidelines set by the International Brachial Artery Reactivity Task Force (32), endothelial 
dysfunction marker brachial FMD was assessed at each visit using a GE Logic e high resolution 
ultrasound machine with a 15MHz vascular transducer. FMD measurements were made using 
AccessPoint 2011 software (Freeland Systems, Version 8.2). Specifically, participants laid 
supine with a blood pressure cuff placed on the forearm, which was inflated to 250 mmHg for 5 
minutes. The brachial artery dilation was measured in response to reactive hyperemia at 60 and 
90 seconds post-cuff deflation, and the maximum value was retained. FMD was calculated as the 
percent increase in the diameter of the brachial artery. 
Because participants underwent two entry visits, the IL-6, CRP, D-dimer, and FMD 
values for these visits were averaged to increase the stability of the baseline estimates. The 0-to-
12-week and 12-to-24-week change scores for each outcome variable were calculated as 12-
week minus baseline and 24-week minus 12-week, respectively. The 0-to-12-week change scores 
reflect treatment phase changes in the outcome variables, while the 12-to-24-week change scores 
reflect follow-up phase changes. More negative values indicate greater improvement for IL-6, 
CRP, and D-dimer, whereas more positive values indicate greater improvement for FMD. Of 
note, no variable transformations were necessary as all outcome variables were approximately 
normally distributed. 
Covariates. The included covariates were age, sex, race/ethnicity, Framingham risk score 
(FRS), and baseline depressive symptoms. Age (years), sex at birth (0 = female, 1 = male), and 
race/ethnicity were assessed via chart review at the screening visit. Due to low counts in some 
racial and ethnic categories, we re-coded race/ethnicity into a dichotomous variable. Specifically, 
we collapsed the race (White, Black/African American, Asian, Native Hawaiian/Pacific Islander, 
American Indian, Other, Declined) and ethnicity (non-Hispanic/Latino, Hispanic/Latino, 
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unknown) variables into race/ethnicity (0 = non-Hispanic Black, 1 = Other). FRS was calculated 
using a validated formula consisting of age (via chart review at screening visit), smoking status 
(via self-report at second entry visit), diabetes status (via chart review at second entry visit), and 
objectively measured systolic blood pressure, total cholesterol, and high-density lipoprotein 
cholesterol at the second entry visit (33). Of note, the FRS was chosen because evidence 
suggests that this tool more accurately captures CVD risk among PLWH than the ACC/AHA 
Pooled Cohort Equations (PCEs), the Systematic COronary Risk Evaluation (SCORE), and the 
Data Collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study equation (34). However, 
it is acknowledged that, overall, the existing CVD risk prediction models for the general 
population underestimate CVD risk in the HIV population (35). Baseline depressive symptoms 
were measured using the Hopkins Symptom Checklist Depression Scale (SCL-20) (36-39) at the 
second entry visit. The three sleep-related items (i.e., “trouble falling asleep,” “awakening in the 
early morning,” and “sleep that is restless or disturbed”) were not included in the total depression 
score calculation, given their overlap with the exposure variable. Thus, we subsequently refer to 
this variable as SCL-17. The two variables used in the sensitivity analyses described below are 0-
to-12-week changes in depressive symptoms and randomization status. The 0-to-12-week SCL-
17 change score was calculated as 12-week minus second entry. Randomization status (0 = usual 
care, 1 = BtB) was based on participant randomization to either BtB or usual care at the second 
entry visit.  
Statistical analysis 
 All analyses were performed using IBM SPSS software (v. 26). Participant characteristics 
were summarized using descriptive statistics. Specifically, continuous variables were 
summarized as mean (standard deviation; SD), and categorical variables were summarized as 
frequency (%). Within-person mean imputation was used for self-report questionnaires (i.e., 
PSQI and SCL-17) if  25% of items were missing. We used component scores for the PSQI and 
items for the SCL-17 when assessing missingness and imputing missing values.  
To examine associations between 0-to-12-week changes in sleep disturbance and 0-to-12-
week and 12-to-24-week changes in inflammatory, coagulation, and endothelial dysfunction 
markers, we constructed eight multivariate linear regression models (see Figure 1). Four models 
examined the adjusted association between 0-to-12-week changes in sleep disturbance and 0-to-
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12-week changes in each outcome variable (IL-6, CRP, D-dimer, and FMD). Four models 
examined the adjusted associations between 0-to-12-week changes in sleep disturbance and 12-
to-24-week changes in each outcome variable. All models included the following covariates: age, 
sex, race/ethnicity, FRS, and baseline depressive symptoms. Due to the small sample sizes, it is 
highly likely that these models are underpowered to detect the associations of interest. Thus, we 
made the decision to proceed with a tentative interpretation of standardized regression 
coefficients (βs)  0.10 or ≤ -0.10 in order to characterize these associations in the variables’ 
original units and assess whether they may be clinically meaningful. 
 We additionally conducted two types of sensitivity analyses. First, to examine the 
influence of changes in depressive symptoms on the associations of interest, we replaced the 
baseline depressive symptoms variable with the 0-to-12-week changes in depressive symptoms 
variable in each of the eight models. Second, to examine the influence of trial arm on the 
associations of interest, we added the randomization status variable to each of the eight models. 
Results 
Participant characteristics 
Participant characteristics by analytic cohort are displayed in Table 2.1. Of note, due to 
the eligibility criteria of the parent study, all participants have high ART adherence, are 
relatively healthy (e.g., did not have pre-existing cardiovascular conditions), and screened 
positive for depression. The average age was approximately 45 years, the vast majority of 
participants were male, and roughly half were non-Hispanic Black. Overall, the 10-year CVD 
risk was in the low range (~10%) based on the Framingham risk score, although this may 
underestimate the CVD risk of PLWH. The mean SCL-17 total score was 2.2 (possible range 0-
4), which falls in the severe depression range. The mean PSQI global score was 10-11 (possible 
range 0-21), above the recommended cut-off of 5 to identify “poor sleepers.” This appears higher 
than other HIV samples observing mean PSQI global scores of approximately 6 (40, 41). 
Changes over time in the exposure and outcome variables 
On average, participants displayed an improvement in sleep disturbance as evidenced by 
a mean decrease of 1.2-1.6 PSQI points between the second entry and 12-week visits. We 
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observed good variability in the PSQI change score, with an average SD of approximately 3 
points (see Table 2.2 for biomarker analytic cohorts and Table 2.3 for FMD analytic cohorts).  
For the 0-to-12-week period, we observed an increase (worsening) in inflammatory 
markers IL-6 and CRP of 0.69 pg/mL and 0.45 mg/L, respectively, but a decrease (improvement) 
in coagulation marker D-dimer of 24 ng/mL (see Table 2.2). We also observed an increase 
(improvement) in endothelial dysfunction marker FMD of 0.28% (see Table 2.3). The 0-to-12-
week change scores for IL-6, CRP, D-dimer, and FMD all displayed good variability, with SD’s 
of 2.88 pg/mL, 2.92 mg/L, 554 ng/mL, and 2.76%, respectively.  
For the 12-to-24-week period, we observed a similar pattern for CRP and D-dimer, as 
both maintained the same direction in their change scores. However, we observed the opposite 
direction in change scores for IL-6 and FMD, with a decrease (improvement) in IL-6 and a 
decrease (worsening) in FMD. The 12-to-24-week change scores for IL-6, CRP, D-dimer, and 
FMD showed good variability, with SD’s of 3.03 pg/mL, 4.63 mg/L, 680 ng/mL, and 2.86% 
respectively.  
0-to-12-week changes  
There were no statistically significant associations between 0-to-12-week changes in 
sleep disturbance and 0-to-12-week changes in IL-6, CRP, D-dimer, or FMD (see Table 2.4). 
However, we continued with interpretation for βs  0.10 or ≤ -0.10 in order to characterize these 
associations in the variables’ original units and assess whether they may be clinically meaningful 
but missed due to type II error. Two of the four examined associations had a β beyond our cut 
points, specifically IL-6 (β = -0.141) and D-dimer (β = -0.144). For every 1-SD (2.9 PSQI points) 
increase (worsening) in the sleep disturbance change score, the IL-6 change score decreased 
(improved) by 0.41 pg/mL (-0.141 x 2.88), and the D-dimer change score decreased (improved) 
by 80 ng/mL (-0.144 x 554). Interestingly, the observed negative associations are in the opposite 
of the expected direction, with increases in sleep disturbance potentially associated with 
decreases, rather than increases, in these biomarkers implicated in HIV-CVD.  
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12-to-24-week changes 
There were no statistically significant associations between 0-to-12-week changes in 
sleep disturbance and 12-to-24-week changes in IL-6, CRP, D-dimer, or FMD (see Table 2.4). 
Three of the four examined associations had a β beyond our cut points, specifically CRP (β = 
0.137), D-dimer (β = 0.163), and FMD (β = 0.287). Among the biomarker analytic cohort, for 
every 1-SD (3.0 PSQI points) increase (worsening) in the sleep disturbance change score, the 
CRP change score increased (worsened) by 0.63 mg/L (0.137 x 4.63), and the D-dimer change 
score increased (worsened) by 111 ng/mL (0.163 x 680). Among the FMD analytic cohort, for 
every 1-SD (2.9 PSQI points) increase (worsening) in sleep disturbance change score, the FMD 
change score increased (improved) by 0.82% (0.287 x 2.86). In contrast to the 0-to-12-week 
results, we observed the expected positive associations, with increases in sleep disturbance 
potentially associated with increases in CRP and D-dimer. However, we observed the opposite of 
the expected negative association between changes in sleep disturbance and FMD, with increases 
in sleep disturbance potentially associated with increases, rather than decreases, in FMD.  
Sensitivity analyses 
 Results of the two sensitivity analyses are presented in Table 2.5. Sensitivity analysis #1, 
in which we replaced baseline depressive symptoms with 0-to-12-week changes in depressive 
symptoms, yielded nearly identical results to the primary results. For both the 0-to-12-week 
changes and the 12-to-24-week changes in the outcome variables, there were no statistically 
significant associations. However, for the 0-to-12-week results, all four of the examined 
associations had βs  0.10 or ≤ -0.10, with the βs for CRP and FMD now beyond the cut points 
despite not appearing to be much different in magnitude from the primary results (βs = 0.128 and 
-0.115 versus 0.092 and -0.093, respectively). Thus, we now observed the expected positive 
association between changes in sleep disturbance and changes in CRP and the expected negative 
association between changes in sleep disturbance and changes in FMD.  
 Sensitivity analysis #2, in which we added randomization status, also yielded nearly 
identical results. For both the 0-to-12-week changes and the 12-to-24-week changes in the 
outcome variables, there were no statistically significant associations. However, for the 0-to-12-
week results, three of the four examined associations had βs  0.10 or ≤ -0.10, with the β for 
 40 
CRP now beyond the cut point despite having a similar magnitude to the primary results (β 
= .103 versus .092). Thus, we again observed the expected positive association between changes 
in sleep disturbance and changes in CRP. For the 12-to-24-week results, two of the four 
examined associations had βs  0.10 or ≤ -0.10, with the β for CRP now falling short of the cut 
point despite having a similar magnitude to the primary results (β = .090 versus .137). 
Discussion 
Our study adds to the scarce literature on associations of sleep disturbance with markers 
of systemic inflammation among PLWH and, to our knowledge, is the first to examine 
associations of sleep disturbance with markers of coagulation and endothelial dysfunction in the 
HIV population. Overall, we did not detect any statistically significant relationships between 
changes in sleep disturbance and changes in IL-6, CRP, D-dimer, or FMD over time in this 
analysis of data from our 24-week pilot randomized controlled trial examining the effect of 
computerized CBT for depression on CVD risk markers in PLWH. Given the novelty of our 
research questions and the low statistical power due to our small sample size, we further 
examined all relationships with βs  0.10 or ≤ -0.10 to assess whether they may be clinically 
meaningful. Five of the eight examined associations were potentially meaningful based on these 
cut points. Specifically, we observed a potential signal for a negative relationship between 
changes in sleep disturbance and concurrent changes in IL-6 and D-dimer. These were in the 
opposite of the expected direction, with each 1-SD increase in sleep disturbance (worsening) 
potentially associated with decreases (improvements) in IL-6 and D-dimer of 0.41 pg/mL and 80 
ng/mL, respectively. Furthermore, we observed a potential signal for a positive relationship 
between changes in sleep disturbance and subsequent changes in CRP, D-dimer, and FMD. 
These were in the expected direction for CRP and D-dimer but the opposite direction for FMD, 
with each 1-SD increase in sleep disturbance (worsening) potentially associated with increases 
(worsening) in CRP and D-dimer of 0.63 mg/L and 111 ng/mL, respectively, and with an 
increase (improvement) in FMD of 0.82%.  
Evaluating the clinical meaningfulness of these relationships is difficult due to the lack of 
standard norms for the examined biomarkers and FMD among PLWH. The Strategies for 
Management of Antiretroviral Therapy (SMART) study observed that 1-SD increases (values not 
reported) in IL-6, CRP, and D-dimer were associated with a 39%, 43%, and 40% greater risk of 
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CVD, respectively (42). In the present study, the changes in these biomarkers associated with a 
1-SD increase in sleep disturbance were much smaller than the SDs for these outcomes at 
baseline (see Table 2), suggesting that these associations may not be clinically meaningful. To 
our knowledge, no study has examined the value of FMD in predicting CVD risk among PLWH, 
although general population research suggests that a 1% increase in FMD is related to a 12% 
decreased risk of future CVD events (43). When compared to this, our finding that a 3-point 
increase in PSQI total score may be associated with a 0.82% increase in FMD appears to be 
potentially meaningful, although in the opposite of the expected direction. The reasons for this 
unexpected association are currently unclear, and future studies are needed to assess the 
reproducibility of this finding and to explore potential underlying causes. 
Only four studies, all cross-sectional, have examined associations between various 
measures of sleep disturbance and inflammatory markers among PLWH, and the results have 
been mixed. Two studies utilized actigraphy-derived sleep parameters indicative of sleep 
disturbance. Lee et al. (23) found positive correlations with wake after sleep onset for TNF-alpha 
(rho = .121, p = .042) and CRP (rho = .135, p = .023) but not for IL-6. In that study, no 
associations were observed between total sleep time and the inflammatory markers. In contrast, 
Wirth et al. (21) found higher CRP and IL-6 in people with lower total sleep time but did not 
observe group differences in inflammatory markers for wake after sleep onset, sleep latency, or 
sleep efficiency. The other two studies utilized self-reported sleep disturbance. Gay et al. (22) 
did not find group differences in inflammatory markers IL-6, TNF-alpha, or CRP between 
people with higher versus lower self-reported sleep onset latency. Moore et al. (24) did observe 
associations but in the opposite of the expected direction. Specifically, they observed negative 
correlations with global sleep disturbance for TNF-gamma (rho = -.697, p = .017) and TNF-
alpha (rho = -.697, p = .017) but not for IL-6 among women living with HIV. No significant 
associations were observed between sleep disturbance and the inflammatory markers among men 
living with HIV. Of note, this study utilized a very small sample (N = 20, 11 women and 9 men).  
In contrast to these prior studies, we examined changes over time in sleep disturbance. 
However, we may still observe consistencies and inconsistencies with the existing literature. Our 
CRP results suggest that changes in sleep disturbance may be unrelated to concurrent changes in 
systemic inflammation, consistent with the null results observed by Gay et al. (22), but related to 
subsequent changes. However, our results are inconsistent with the positive, cross-sectional 
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associations between sleep disturbance and CRP found by Wirth et al. (21) and Lee et al. (23). 
We observed a negative association between changes in sleep disturbance and concurrent 
changes in IL-6, inconsistent with all four studies that found either positive or null cross-
sectional relationships (21-24). These inconsistent results may be due to differences in the 
assessments of sleep disturbance and/or differences in HIV-related sample characteristics (e.g., 
percentage of participants with suppressed viral loads). As this area grows, future research will 
be able to explore potential moderators that may help account for these mixed results.  
There are several potential explanations for our results. First, we observed potentially 
meaningful associations in the expected direction between changes in sleep disturbance and 
subsequent changes in CRP and D-dimer. This suggests that sleep disturbance may influence 
some of the pathophysiological mechanisms underlying HIV-CVD. The mechanisms by which 
sleep disturbance may be related to systemic inflammation and coagulation are poorly 
understood, with existing evidence largely based on intentional sleep restriction or deprivation 
studies. One hypothesis linking sleep deprivation to inflammation proposes that the reduced 
opportunity for nighttime blood pressure dipping leads to the activation of vascular endothelium, 
which results in the production of cellular adhesion molecules and inflammatory cytokines (e.g., 
IL-6) (44). Second, we also observed potentially meaningful results in the opposite of the 
expected direction for changes in sleep disturbance and concurrent changes in IL-6 and D-dimer 
and subsequent changes in FMD. It is possible that the present study’s methodology played a 
role in these unexpected findings. Our results need to be considered within the context of a 
depression clinical trial – our sample consisted entirely of depressed adults living with HIV, half 
of whom received CBT for depression. While we attempted to statistically control for the 
potential effects of depressive symptoms and randomization study group on our outcomes, this 
may have been insufficient. It is unknown whether the relationships between sleep disturbance 
and putative biological mechanisms of HIV-CVD differ based on depression status. Third, we 
observed null results, suggesting that there may be no meaningful relationships between changes 
in sleep disturbance and concurrent changes in CRP and FMD and subsequent changes in IL-6. 
One possible explanation for our null results is the limitation of our sleep assessment. While the 
PSQI is correlated with measures specifically assessing insomnia symptoms (31), its components 
go beyond diagnostic criteria (e.g., sleep medication use). This reduced content validity may 
have negatively impacted our ability accurately capture participant experiences of insomnia 
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symptoms. Another potential explanation for our null results is that behavioral, rather than 
biological, pathways are responsible for the insomnia-CVD relationship among PLWH. For 
example, others have found that insomnia is related to suboptimal ART adherence (45, 46), 
potentially leading to inconsistently managed HIV and thus increasing the risk for CVD.   
The present study has limitations worthy of consideration. First, our small sample size 
resulted in underpowered analyses limiting our ability to detect potentially meaningful 
associations. Second, we utilized a global measure of sleep disturbance, which does not 
specifically capture insomnia symptoms. Third, our analyses were within the context of a 
depression clinical trial, with participants screening positive for clinically significant depression 
at study entry. Despite these limitations, examining data from the parent trial offered a unique 
opportunity to examine associations between changes in sleep disturbance and changes in 
markers of systemic inflammation, coagulation, and endothelial dysfunction over time in a 
sample of adults with well-managed HIV. 
In sum, we did not detect any statistically significant associations between changes in 
sleep disturbance and changes in IL-6, CRP, D-dimer, and FMD over time. However, we did 
observe potentially meaningful associations based on the magnitude of the standard regression 
coefficients, although some associations were in the opposite of the expected direction. Due to 
the dearth of research in this area and the limitations of the current studies, there is a need for 
additional investigations examining associations between insomnia and the putative biological 
mechanisms underlying HIV-CVD. Future studies should be adequately powered, utilize 
comprehensive insomnia assessments based on diagnostic criteria (e.g., Insomnia Severity 
Index), and assess and control for depressive symptoms to determine insomnia’s independent 
association. Ultimately, identifying the mechanisms underlying the insomnia-CVD relationship 
in PLWH could inform the development or selection of interventions designed to help lower the 
risk of HIV-CVD. 
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Table 2.1  
Participant Characteristics at Study Entry by Analytic Cohort 
 0-to-12-week 
biomarker (n = 37) 
0-to-12-week  
FMD (n = 38) 
12-to-24-week 
biomarker (n = 33) 
12-to-24-week  
FMD (n = 33) 
Age, years 45.3 (11.7) 44.6 (11.8) 45.7 (11.1) 45.6 (11.1) 
Sex, % female 4 (10.8) 3 (7.9) 3 (9.1) 3 (9.1) 
Race/ethnicity, % non-Hispanic Black 20 (54.1) 22 (57.9) 17 (51.5) 20 (60.6) 
FRS, 10-year CVD risk % 9.5 (5.06) 9.7 (5.1) 9.5 (4.7) 10.2 (5.1) 
HDL cholesterol, mg/dL 20.9 (5.10) 20.9 (5.1) 21.1 (5.3) 10.6 (5.1) 
Total cholesterol, mg/dL 86.4 (15.3) 86.5 (15.4) 87.1 (15.4) 86.9 (15.7) 
SBP, mmHg 126.4 (11.9) 127.1 (12.0) 126.3 (11.4) 128.3 (11.3) 
Antihypertensive medication, % yes 10 (27.0) 10 (26.3) 9 (27.3) 9 (27.3) 
Current smoker, % yes 14 (37.8) 16 (42.1) 11 (33.3) 14 (42.4) 
Diabetes, % yes 1 (2.7) 2 (5.3) 1 (3.0) 2 (6.1) 
SCL-17 total score (possible range: 0-4) 2.2 (0.8) 2.2 (0.8) 2.2 (0.8) 2.2 (0.8) 
Note. Continuous variables are presented as mean (standard deviation). Categorical variables are presented as n (%). The four analytic cohorts are non-
exclusive with overlap of participants between cohorts (see Study design, setting, and participants). 
FMD = flow-mediated dilation; FRS = Framingham risk score; CVD = Cardiovascular disease; HDL = high-density lipoprotein; SBP = systolic blood 
pressure; SCL-17 = Hopkins Symptom Checklist Depression Scale without the 3 sleep-related items (see Methods). 
 49 
Table 2 2 
Sleep Disturbance and Biomarker Values at Each Time Point by Analytic Cohort 
 0-to-12-week 
biomarker (n = 37) 
12-to-24-week 
biomarker (n = 33) 
PSQI (possible range: 0-21)   
Entry 11.0 (3.9) 10.9 (4.0) 
12-week 9.4 (4.5) 9.4 (4.7) 
24-week --- --- 
Change score -1.6 (2.9) -1.5 (3.0) 
IL-6, pg/mL   
Entry 2.56 (1.97) --- 
12-week 3.24 (3.11) 3.12 (3.16) 
24-week --- 2.73 (2.37) 
Change score 0.69 (2.88) -0.39 (3.03) 
CRP, mg/L   
Entry 4.59 (4.61) --- 
12-week 5.03 (5.65) 4.85 (6.63) 
24-week --- 5.00 (5.51) 
Change score 0.45 (2.92) 0.15 (4.63) 
D-dimer, ng/mL   
Entry 2444 (831) --- 
12-week 2420 (513) 2406 (514) 
24-week --- 2400 (786) 
Change score -24 (554) -6 (680) 
Note. Variables are presented as mean (standard deviation). Change scores were calculated as 
12-week minus second entry and 24-week minus 12-week. The two analytic cohorts are non-
exclusive with overlap of participants between cohorts (see Study design, setting, and 
participants). 
PSQI = Pittsburgh Sleep Quality Index; IL-6 = interleukin-6; CRP = C-reactive protein. 
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Table 2.3  
Sleep Disturbance and FMD Values at Each Time Point by Analytic Cohort 
 0-to-12-week  
FMD (n = 38) 
12-to-24-week  
FMD (n = 33) 
PSQI (possible range 0-21)   
Entry 11.5 (3.9) 11.3 (4.0) 
12-week 9.9 (4.5) 10.1 (4.5) 
24-week --- --- 
Change score -1.6 (2.9) -1.2 (2.9) 
FMD, %   
Entry 2.90 (1.72) --- 
12-week 3.18 (2.71) 3.34 (2.82) 
24-week --- 2.12 (2.12) 
Change score 0.28 (2.76) -1.22 (2.86) 
Note. Variables are presented as mean (standard deviation). Change scores were calculated as 
12-week minus second entry and 24-week minus 12-week. The two analytic cohorts are non-
exclusive with overlap of participants between cohorts (see Study design, setting, and 
participants). 
FMD = flow-mediated dilation; PSQI = Pittsburgh Sleep Quality Index. 
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Table 2.4  
Multivariate Linear Regression Models Examining Associations of 0-to-12-Week Changes in Sleep 
Disturbance with 0-to-12-Week and 12-to-24-Week Changes in Biomarkers and FMD 
 B SE β p-value 
0-to-12-week     
Changes in IL-6 -.138 .184 -.141 .458 
Changes in CRP .092 .186 .092 .625 
Changes in D-dimer -27.06 31.73 -.144 .401 
Change in FMD -.088 .176 -.093 .620 
12-to-24-week     
Changes in IL-6 .050 .213 .050 .817 
Changes in CRP .210 .307 .137 .500 
Changes in D-dimer 36.56 45.95 .163 .433 
Change in FMD .283 .175 .287 .117 
Note. Models adjusted for age, sex, race/ethnicity, Framingham risk score, and baseline 
depressive symptoms. 
FMD = flow-mediated dilation; B = unstandardized regression coefficient; SE = standard 
error; β = standardized regression coefficient; IL-6 = interleukin-6; CRP = C-reactive protein. 
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Table 2.5  
Sensitivity Analyses of Multivariate Linear Regression Models Examining the Association Between 
Changes in 0-to-12-Week Insomnia Symptoms and Changes in Biomarkers and FMD 
 B SE β p-value 
Sensitivity analysis #1     
0-to-12-week     
Changes in IL-6 -.103 .184 -.104 .581 
Changes in CRP .127 .185 .128 .498 
Changes in D-dimer -25.09 31.63 -.133 .434 
Change in FMD -.109 .174 -.115  .535 
12-to-24-week     
Changes in IL-6 .034 .211 .034 .874 
Changes in CRP .167 .303 .109 .585 
Changes in D-dimer .289 45.78 .171 .408 
Change in FMD .289 .174 .293 .108 
     
Sensitivity analysis #2     
0-to-12-week     
Changes in IL-6 -.129 .189 -.131 .500 
Changes in CRP .102 .190 .103 .596 
Changes in D-dimer -22.96 32.21 -.122 .482 
Change in FMD -.092 .179 -.097 .611 
12-to-24-week     
Changes in IL-6 -.047 .214 -.047 .830 
Changes in CRP .138 .321 .090 .671 
Changes in D-dimer 31.44 48.47 .140 .522 
Change in FMD .284 .171 .288 .109 
Note. Sensitivity analysis #1 adjusted for age, sex, race/ethnicity, Framingham risk score, and 
0-to-12-week changes in depressive symptoms. Sensitivity analysis #2 adjusted for age, sex, 
race/ethnicity, Framingham risk score, baseline depressive symptoms, and randomization 
status. 
FMD = flow-mediated dilation; B = unstandardized regression coefficient; SE = standard 
error; β = standardized regression coefficient; IL-6 = interleukin-6; CRP = C-reactive protein 
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Figure 2.1. Visual representation of the examined associations between 0-to-12-week changes in sleep 
disturbance and 0-to-12-week and 12-to-24-week changes in interleukin-6 (IL-6), C-reactive protein 
(CRP), D-dimer, and brachial flow-mediated dilation (FMD). 
 
 
 
 
 
 APPENDIX 
DISSERTATION PROPOSAL 
Cardiovascular disease (CVD) is now one of the leading causes of death in people with human 
immunodeficiency virus (HIV).1-3 Meta-analytic findings indicate that HIV+ adults on antiretroviral 
therapy (ART) have a 1.6-2.0 times greater risk of CVD than uninfected adults.4 Leading 
candidate mechanisms underlying HIV-CVD include immune activation, systemic inflammation, 
altered coagulation, and endothelial dysfunction.5 However, immune activation, inflammatory, 
coagulatory, and endothelial dysfunction markers are only partially improved by ART,6-9 and 
HIV+ adults on ART achieving lower viral loads continue to exhibit a 39% greater risk of acute 
myocardial infarction (MI).10 Thus, there is a current need to identify novel, modifiable risk 
factors for HIV-CVD that can be targeted by primary CVD prevention approaches.  
Insomnia is a potential risk factor for CVD in HIV that has been ignored thus far. In the general 
population, evidence indicates that insomnia is a predictor of future CVD events,11-13 – 
independent of traditional CVD risk factors and depression. Leading candidate mechanisms 
underlying the insomnia-CVD relationship mirror those underlying the HIV-CVD relationship – 
namely, systemic inflammation, altered coagulation, and endothelial dysfunction.14-16 Though the 
relationship between insomnia and immune activation has not been studied in the general 
population, immune activation is closely related to systemic inflammation and an important 
feature of HIV pathophysiology.17 Importantly, the largest RCT of behavioral interventions for 
insomnia in older adults (N=123) found that cognitive-behavioral therapy for insomnia (CBT-I), 
versus a sleep seminar, significantly reduced the risk of high C-reactive protein (CRP) at 1-year 
follow-up (OR=0.26).18 CRP is an inflammatory marker implicated in atherosclerosis and 
predictive of future CVD events.19 An additional analysis of this RCT indicated that CBT-I 
significantly reduced proinflammatory cytokine gene expression at post-treatment, suggesting a 
genomic mechanism through which insomnia treatment reduces systemic inflammation.20 At 
present, little is known about insomnia’s potential contribution to HIV-CVD. It is now important to 
evaluate insomnia in this regard because: a) insomnia is a common complaint in the HIV 
population (58%)21 and b) initial evidence suggests that greater sleep disturbance may be 
related to higher levels of inflammatory markers implicated in CVD in HIV+ samples.22-24 
My long-term goal is to direct a program of research aimed at preventing CVD in HIV by 
identifying and intervening on psychosocial risk factors for CVD in HIV. In line with this goal, my 
Master’s thesis examined insomnia symptoms as a predictor of atherosclerotic CVD in HIV+ 
veterans. In further pursuit of this goal, the proposal seeks to examine associations of insomnia 
and insomnia changes over time with the putative mechanisms of HIV-CVD. I am in a unique 
position to complete the proposal and accelerate my trajectory as an independent scholar 
because: (a) my sponsor and co-sponsors were the first to examine psychosocial contributors 
(i.e., depression) to CVD in HIV,25,26 and (b) through my sponsor and co-sponsors, I will be able 
to leverage two unique data sources: the Veterans Aging Cohort Study (VACS) Biomarker 
Cohort and a 24-week RCT (R01HL126557). The specific aims of this application are: 
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Aim 1: To determine the associations of insomnia symptoms with circulating levels of 
immune activation, systemic inflammation, and coagulation markers in HIV+ adults. 
We hypothesize that, among HIV+ veterans in the VACS Biomarker Cohort, insomnia 
symptoms (self-report) will be positively associated with circulating levels of the immune 
activation marker soluble CD14 (sCD14), systemic inflammation marker interleukin-6 (IL-6), and 
coagulation marker D-dimer – the latter two of which are predictive of future CVD events in 
HIV.27 The VACS Biomarker Cohort, an observational study of HIV+ veterans (N=1,542), is a 
subsample of the VACS 8 site study. Existing data was merged with new queries of the VA 
electronic medical record system. 
 
Aim 2: To determine the associations of changes in insomnia symptoms over time with 
changes in systemic inflammation, coagulation, and endothelial dysfunction markers 
over time in HIV+ adults. 
We hypothesize that, in a 24-week RCT of HIV+ adults on effective, continuous ART (N=51; 
R01HL126557), changes in insomnia symptoms (self-report) from Week 0 to 12, will predict 
changes in the systemic inflammation markers IL-6 and CRP, the coagulation marker D-dimer, 
and the endothelial dysfunction marker brachial flow-mediated dilation (FMD) from Week 12 to 
24. Brachial FMD is related to inflammatory and coagulatory markers in adults with HIV28 and is 
predictive of future CVD events in the general population.29 
Support for these hypotheses would provide preliminary evidence that insomnia may be a 
modifiable contributor to immune activation, inflammation, coagulation, and endothelial 
dysfunction in people with HIV. In turn, this new knowledge would provide the mechanistic 
rationale for a future RCT testing whether treating insomnia in people with HIV helps to prevent 
clinical CVD onset. Ultimately, this line of research could identify novel targets for primary CVD 
prevention approaches in people with HIV. 
RESEARCH STRATEGY 
A. Significance 
(A1) CVD: A Leading Health Concern in the HIV-Infected Population 
CVD is now one of the leading causes of death in people with HIV.1-3 HIV-CVD has been 
attributed to the virus itself,30-32 ART treatment, 33,34 and both traditional 35 and non-traditional 
(e.g., renal disease and hepatitis C co-infection)36,37 CVD risk factors. However, excess CVD 
risk remains among HIV+ adults after controlling for HIV viral load, ART use, and CVD risk 
factors,10 and among HIV+ adults on newer ART regimens free of the dysmetabolic effects.33 
Furthermore, when comparing HIV+ and uninfected adults free of traditional CVD risk factors, 
HIV+ adults continue to exhibit twice the risk of MI.38 These findings indicate that HIV+ adults 
are at a disproportionately higher risk of CVD than uninfected adults independent from HIV 
infection, ART, and traditional CVD risk factors, prompting the examination of other potential, 
and treatable, etiologies of HIV-CVD. 
(A2) Biological Etiologies of HIV-CVD: Immune Activation, Systemic Inflammation, 
Altered Coagulation, and Endothelial Dysfunction 
Numerous reviews suggests immune activation, systemic inflammation, altered 
coagulation, and endothelial dysfunction as putative mechanisms of HIV-CVD.5,39-41 HIV+ adults 
exhibit elevated markers of immune activation (e.g., sCD14, soluble CD163), systemic 
inflammation (e.g., IL-6, high sensitivity CRP), and altered coagulation (e.g., D-dimer), and 
increased endothelial dysfunction (e.g., reduced brachial FMD and elevated soluble VCAM-1).41  
In turn, markers of these mechanisms have been associated with measures of subclinical CVD 
or clinical CVD. Specifically, immune activation marker sCD14 and T-cell activation markers are 
positively associated with coronary artery calcification (CAC)42 and carotid artery plaque.43 A 
recent systematic review of the relationships between inflammatory and coagulatory markers 
and CVD in HIV found that IL-6, CRP, and D-dimer were associated with the occurrence of 
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future CVD in three out of four studies.27 While studies examining brachial FMD as a predictor of 
future CVD in HIV+ samples are lacking, evidence suggests that endothelial dysfunction is 
associated with HIV-related altered coagulation.28 Moreover, in the general population, brachial 
FMD is an independent predictor of incident CVD,29 and intervention-related improvements in 
FMD predicts a reduced incidence of CVD events.44-46 
While ART has been successful in reducing HIV viral loads and improving some markers 
of immune function (e.g., CD4+ T-cell counts), it does not entirely eradicate reservoirs of viral 
replication47 or fully normalize markers of immune activation, inflammation, or coagulation.6-9 
Likewise, ART does not normalize markers of endothelial functioning.9,48 Thus, there is a need 
to continue the search for other novel, modifiable risk factors of HIV-CVD with the potential to 
effect these mechanisms. 
(A3) Insomnia as an independent, clinically meaningful risk factor for CVD in the general 
population. 
 A potential, modifiable risk factor of CVD in the general population is insomnia. Insomnia 
symptoms include (a) dissatisfaction with sleep quantity and/or quality associated with 
difficulties initiating, maintaining, or returning to sleep, (b) clinically significant distress or 
impairment in functioning, and (c) frequency of sleep difficulties ≥3 nights/week for ≥3 months, 
despite the opportunity for sleep.49,50 Current diagnostic manuals conceptualize insomnia as an 
independent clinical problem, regardless of its occurrence with or without co-morbid psychiatric 
conditions.49,50 In support of this notion, previous research indicates that 10-54% of chronic 
insomnia cases occur without the presence of depressive symptoms.51-55 Additionally, insomnia 
is a more consistent predictor of future depression56,57 than depression is of future insomnia.58-62 
Taken together, this evidence challenges the common assumption that insomnia occurs solely 
or most often as a symptom of depression. This view is supported by recent diagnostic manual 
revisions that identify insomnia as an independent condition warranting clinical attention 
regardless of its manifestation as primary or co-morbid with other conditions.49,50,63 
First, existing research indicates that insomnia is a predictor of CVD in the general 
population, independent of traditional CVD risk factors. To date, three meta-analyses have 
examined insomnia as a predictor of CVD events, all of which have observed significant positive 
associations.11-13 The updated 2014 meta-analysis (17 prospective studies, N=311,260 adults) 
found that those with insomnia symptoms have a 55% greater risk of stroke, 28% greater risk of 
coronary heart disease, 41% greater risk of MI, and 33% greater risk of CVD-related mortality 
than those without insomnia symptoms.12 The subsequent 2017 meta-analysis examining 
individual insomnia symptoms (23 studies, N=160,867) found that difficulty initiating sleep, 
difficulty maintaining sleep, and non-restorative sleep significantly predicted a 27%, 11%, and 
18% increased risk of CVD events, respectively.13 While these meta-analyses do not specifically 
examine the insomnia-CVD relationship independent from traditional CVD risk factors, the 
majority of the studies included in these meta-analyses control for traditional CVD risk factors. 
For instance, in the meta-analysis conducted by Li et al.12 only three out of the seventeen 
included effect sizes did not control for traditional CVD risk factors. Thus, the meta-analytic 
findings are largely based on traditional CVD risk factor adjusted effects. 
Second, sufficient evidence exists to support insomnia as a predictor of CVD in the 
general population, independent of depression. In the updated 2014 meta-analysis, the majority 
of studies controlling for depressive symptoms (four out of six) observed that significant positive 
relationships persisted between insomnia symptoms and CVD.12 Furthermore, a large 
prospective cohort study (N=44,080) found that adults with insomnia disorder and without a 
depressive disorder were at 75% greater risk of incident acute MI and 65% greater risk of 
incident stroke than adults without either condition.64 
Third, the CVD risk conferred by insomnia is clinically meaningful. To illustrate, the risk 
ratios from the insomnia-CVD meta-analyses (RR=1.28-1.55)11-13 are approaching those of 
traditional CVD risk factors, such as diabetes and insufficient levels of high-density lipoprotein.65 
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(A4) The behavioral and biological plausibility of the insomnia-CVD relationship 
 Briefly, as the current proposal will focus on potential biological mechanisms, general 
population research has examined the association between insomnia symptoms and a number 
of behavioral factors that may potentially underlie the insomnia-CVD relationship. Research 
supports a significant positive association between insomnia symptoms and physical 
inactivity,66,67 excessive alcohol use,66 smoking,68,69 and poor diet.67 In addition, research 
indicates that insomnia symptoms increase the risk of incident diabetes70 and incident 
hypertension,71 which have both behavioral and biological aspects. 
 General population research has also examined the association between insomnia 
symptoms and several biological factors that could underlie the insomnia-CVD relationship, 
including the HIV-CVD mechanisms of inflammation, coagulation, and endothelial dysfunction. 
There’s currently no research in the general population examining the relationship between 
insomnia and immune activation. With respect to inflammation, a large body of research 
supports a significant positive association between insomnia symptoms and inflammation. To 
illustrate, a meta-analysis of 72 studies involving >50,000 adults found that insomnia symptoms 
are associated with higher levels of IL-6 and CRP.14 Regarding altered coagulation, less is 
known, but individual study data suggests a significant positive association between sleep 
disturbance and a number of coagulatory factors, including elevated D-dimer,72-74 fibrinogen,15,75-
77 and von Willebrand factor.78 Concerning endothelial dysfunction, individual study data 
suggests a significant inverse association between insomnia symptoms and brachial FMD.79,80 
 Going beyond associations, the strongest evidence indicating that insomnia may play a 
causal role in the development of CVD is provided by the largest (N=123) RCT of behavioral 
interventions for insomnia in older adults.18 This trial found that, among adults with primary 
insomnia (i.e., insomnia without psychiatric co-morbidities), those treated with CBT-I had a 
significantly lower risk (OR=0.26) of elevated CRP (>3.0 mg/L), an inflammatory marker 
predictive of incident CVD,19 than those treated with an educational sleep seminar at 16-months 
follow-up. The observed effect size was similar to that of exercise81 and weight loss.82 
Furthermore, adults whose insomnia remitted during the trial had significantly lower CRP levels 
than those whose insomnia persisted at 16-months follow-up.18 The authors concluded that 
CBT-I is a viable option for modifying an inflammatory marker of CVD risk.18 An additional 
analysis of this RCT indicated that CBT-I, versus the educational sleep seminar, significantly 
reduced proinflammatory cytokine gene expression at 4-montha follow-up, suggesting a 
genomic mechanism through which insomnia treatment reduces inflammation.20 
(A5) Insomnia as a prevention target for HIV-CVD 
  Insomnia and sleep disturbance are receiving increasing attention in people with HIV, 
as evidenced by two qualitative reviews and a meta-analysis.21,83,84 The qualitative reviews 
reported a wide range for the occurrence of sleep disturbance (29-97%),83,84 and the meta-
analysis (27 studies) estimated the occurrence to be 58%.21 However, all three acknowledged 
that the lack of insomnia assessments based on validated measures or diagnostic criteria 
limited their ability to make claims regarding the prevalence of insomnia. Rather, the existing 
literature on sleep disturbance in adults with HIV have largely utilized measures of “informal 
criteria,” the Pittsburgh Sleep Quality Index (PSQI), and the General Sleep Disturbance Scale 
(GSDS). In addition, the majority of the included studies did not exclude or control for 
depressive symptoms.21 As a result, the prevalence of insomnia symptoms in the HIV+ 
population is unknown, but the number of adults with HIV experiencing subjective sleep 
complaints appears to be high. Thus, should insomnia be implicated in HIV-CVD, it would be a 
primary CVD prevention target applicable to a large portion of the HIV+ population. 
 Among the HIV+ population, no published research has examined insomnia as a 
predictor of future CVD. However, preliminary evidence from my completed Master’s thesis 
project suggests that highly bothersome insomnia symptoms are an independent predictor of 
atherosclerotic CVD among HIV+ veterans (see Approach C1 for details). In addition, initial 
 58 
evidence exists indicating that sleep disturbance is cross-sectionally associated with higher 
levels of IL-6, CRP, and inflammation-related single nucleotide polymorphisms in people with 
HIV.22-24 However, these studies failed to control for depressive symptoms and are limited by 
small samples sizes. No studies thus far have examined the insomnia-immune activation 
relationship. Likewise, no studies thus far have examined the longitudinal associations between 
insomnia symptoms and immune activation, systemic inflammation, altered coagulation, or 
endothelial dysfunction. Thus, an investigation of the relationship between insomnia and these 
putative mechanisms of HIV-CVD is warranted.  
(A6) Scientific Premise of and Current Need for the Proposed Research 
 The foundation on which the proposed research is built is strong. In the general 
population, substantial evidence indicates that insomnia is a clinically meaningful predictor of 
CVD, independent of traditional CVD risk factors and depression, and that inflammation, 
coagulation, and endothelial dysfunction may, in part, explain the excess CVD risk in people 
with insomnia. In the HIV+ population, sleep disturbance is a common complaint, and 
preliminary evidence suggests that insomnia is independently associated with atherosclerotic 
CVD risk and inflammatory markers predictive of CVD. Despite this, there remains a large gap 
in our knowledge regarding HIV+ adults that will be addressed by the proposed projects, 
including the (1) cross-sectional associations between insomnia and immune activation, altered 
coagulation, and endothelial dysfunction, (2) the longitudinal associations between insomnia 
and systemic inflammation, altered coagulation, and endothelial dysfunction, and (3) the 
potential for insomnia to serve as a novel target for CVD primary prevention efforts.  
 If the proposed projects’ hypotheses are supported, it would provide preliminary 
evidence that insomnia may be a modifiable driver of immune activation, systemic inflammation, 
altered coagulation, and endothelial dysfunction in people with HIV. In turn, this new knowledge 
would provide the mechanistic rationale for a future RCT testing whether treating insomnia in 
people with HIV could help to prevent the onset of clinical CVD. Ultimately, this line of research 
could identify novel targets for CVD primary prevention approaches in people with HIV that may 
lead to reduced HIV-CVD comorbidity, mortality, and associated costs. 
B. Innovation 
 The proposed projects will be the first to examine associations of insomnia and 
insomnia changes over time with mechanisms thought to underlie CVD in HIV+ adults. We will 
leverage two unique sources of data from HIV+ participants. First, the Aim 1 project will utilize 
the VACS Biomarker Cohort, a large HIV+ cohort that includes VA laboratory, clinical, 
pharmacy, and administrative data. Second, the Aim 2 project will utilize data from a prospective 
RCT, which will allow us to examine associations between changes in insomnia symptoms and 
changes in the putative mechanisms of HIV-CVD. 
C. Approach 
(C1) Preliminary Data 
 In developing my program of research investigating psychosocial risk factors for 
cardiometabolic diseases in 
vulnerable populations, I completed a 
Master’s thesis examining insomnia 
symptoms as an independent risk 
factor for atherosclerotic CVD in HIV+ 
veterans in the VACS Survey Cohort 
(N=6,148). My novel results indicated 
that HIV+ veterans bothered a lot by 
difficulty falling or staying asleep were 
at a 64-77% increased risk of incident 
CVD events (acute MI, coronary artery revascularization, or stroke over an 8-year follow-up 
period) than HIV+ veterans without these symptoms) – independent of demographics, CVD risk 
Table 1. Characteristics of VACS Biomarker Cohort HIV+ 
Participants (N=1,542) 
Age, years (median [Q1, Q3]) 52.1 [46.8, 57.5] 
Sex (% male) 97.3 
Race/Ethnicity (% African American) 69.1 
CD4 cell count, mm3 (% ≥ 500) 34.8 
HIV-1 RNA copies/mL (% < 500) 75.9 
sCD14 pg/mL (median [Q1, Q3]) 1718 [1448, 2085] 
IL-6 pg/mL (median [Q1, Q3]) 2.08 [1.42, 3.38] 
D-dimer ug/mL (median [Q1, Q3]) 0.26 [0.15, 0.49] 
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factors, HIV-specific factors, depressive symptoms, and sleep medication use (ps = .010-.045). 
The aims of this application are a direct extension of my thesis project, as it proposes to 
examine 
underlying 
candidate 
mechanisms of 
HIV-CVD.  
(C2) Methods 
(C2.1) Aim 1: To determine the associations of insomnia symptoms with circulating 
levels of immune activation, systemic inflammation, and coagulation markers in HIV+ 
adults. 
Hypotheses. We hypothesize that insomnia symptoms will be positively associated with sCD14 
(H1), IL-6 (H2) and D-dimer (H3). 
Study Design and Sample. To test these hypotheses, we will conduct an analysis of the VACS 
Biomarker Cohort (N=1,542), an observational study consisting of a subsample of VACS 
participants. VACS is a prospective cohort study launched in 1998 at 8 VA Medical Centers 
continuously enrolling HIV+ patients seen in infectious disease clinics and age-, race-, and 
clinical site-matched uninfected patients seen in general clinics. The VACS Biomarker Cohort 
consists of participants who consented to give blood specimens at an annual exam between 
2005 and 2007.85 All HIV+ participants in the VACS Biomarker Cohort will be included in the 
proposed analyses (see Table 1 for sample characteristics). The VACS Biomarker Cohort 
utilizes data from a number of sources, including a self-report battery administered at enrollment 
and VA laboratory, pharmacy, administrative, and immunology case registry data. 
Statistical Considerations. Independent variable. For H1-H3, we will use the insomnia 
symptoms item on the HIV Symptom Checklist86 completed at enrollment. Participants were 
asked if they had “difficulty falling or staying asleep” during the past 4 weeks, with response 
options of “I do not have this symptom” (0), or “I have this symptoms and it...” “Doesn’t Bother 
Me” (1), “Bothers Me a Little” (2), “Bothers Me” (3), or “Bothers Me a Lot” (4). Responses will be 
used to create a 5-level variable, which will then be used to compute four dummy-coded 
variables with “No Symptoms” as the reference group. This variable is strongly associated, in 
the expected direction, with non-benzodiazepine sleep medication (χ2=192.93, p<.001; see 
Table 2) in the VACS Survey Cohort. 
Dependent variables. The dependent variables are sCD14 (H1), IL-6 (H2), and D-dimer (H3; 
assessment details87). These variables will be analyzed as continuous variables and will be 
logged transformed if significant skew is observed. A recent systematic review reported that IL-6 
and D-dimer are the most commonly assessed biomarkers examining CVD in HIV, with both 
exhibiting significant associations with future CVD events.4 
Covariates. Demographic Variables: age (years), sex (0 = male, 1 = female), and race/ethnicity 
(White [reference], African American, other). Biomedical and Behavioral Confounders: clinical 
CVD (ICD-9 codes for acute MI, unstable angina, revascularization, stroke or transient ischemic 
attack, peripheral vascular disease, or heart failure),10,88 hypertension (no hypertension [<140/90 
mmHg and no antihypertensive medication - reference], controlled hypertension [<140/90 
mmHg with antihypertensive medication], uncontrolled hypertension [≥140/90 mmHg]), diabetes 
(validated metric incorporating glucose measurements, diabetes medication use, and/or at least 
one inpatient or two outpatient ICD-9 codes),89 body mass index (BMI; kg/m2), smoking (never 
[reference], current, former), low-density lipoprotein (LDL) cholesterol, high-density lipoprotein 
(HDL) cholesterol, triglycerides,  statin use (prescription receipt), renal function (estimated 
glomerular filtration rate [eGFR]), hemoglobin, alcohol use (ICD-9 codes and Alcohol Use 
Disorders Identification Test [AUDIT]≥4), cocaine abuse/dependence (ICD-9 codes and self-
report). HIV-Related Factors: HIV-1 RNA levels (<500 or ≥500 copies/mL), CD4 cell count (≥ 
500 [reference], 200-499, or <200 mm3), and ART use (yes/no; prescription receipt). Depressive 
Table 2. Frequencies of insomnia symptoms without and with non-benzodiazepine use 
in the VACS Survey Cohort (N=6,148) 
 0 1 2 3 4 
Without 2,527 (44.0) 491 (8.6) 1,149 (20.0) 832 (14.5) 743 (12.9) 
With 71 (17.4) 22 (5.4) 82 (20.0) 100 (24.9) 131 (32.3) 
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Symptoms and Medications: Patient Health Questionnaire-9 (PHQ-9) total score (without item 
3), non-benzodiazepine sleep medication use (yes/no; prescription receipt), and three 
dichotomous antidepressant medication use variables (prescription receipt): selective serotonin 
reuptake inhibitor (SSRI) antidepressant use, tricyclic antidepressant use (TCA), and other 
antidepressant use. 
Data Analysis. Prior to running hypothesis-testing models, the associations between insomnia 
symptoms and the covariates will be tested using t tests for continuous variables and χ2 tests for 
categorical variables. Next, we will conduct separate linear regression analyses with the 
insomnia symptoms dummy variables as the predictor variables and sCD14 (H1), IL-6 (H2), and 
D-dimer (H3) as the outcome variables. For each hypothesis, we will run six models. Model 1 
(demographic-adjusted): age, sex, race/ethnicity; Model 2 (fully-adjusted): Model 1 + biomedical 
and behavioral confounders + HIV-specific factors; Model 3: Model 2 + non-benzodiazepine 
medication use; Model 4: Model 2 + PHQ-9 total score (without item 3); Model 5: Model 2 + 
antidepressant medication use (SSRI, TCA, other); and Model 6: Model 2 + non-
benzodiazepine medication use, PHQ-9 total score (without item 3), and antidepressant 
medication use. 
Rigorous nature of the research. The Aim 1 methodology ensures a rigorous and transparent 
approach. First, this cohort includes a large number of HIV+ veterans, providing excellent power 
to detect clinically meaningful differences. Second, because of the multiple data sources, we 
can adjust for numerous potential confounders. Third, we propose the use of immune activation, 
systemic inflammation, and coagulation markers most often examined in the HIV-CVD research. 
This provides the ability to connect our findings to existing literature and to facilitate future meta-
analytic examinations. Fourth, our hierarchical linear regression approach assesses the 
relationships of interest with increasing certainty that any observed associations are not due to 
confounders. Anticipated Problems, Alternative Approaches, and Limitations. We do not 
anticipate major problems as we have worked with the insomnia symptoms variable in my 
Master’s thesis and others have worked with the biomarker data. The first limitation of the Aim 1 
project is that results may not generalize to women, as the cohort is predominately male. The 
second limitation of the Aim 1 project is that the cross-sectional data cannot determine 
directionality of associations between insomnia and the biomarkers of interest. These limitations 
will be addressed in our Aim 2 project, as it will include both sexes and utilize a prospective 
design. 
 (C2.2) Aim 2: To determine the associations of changes in insomnia symptoms over time 
with changes in systemic inflammation, coagulation, and endothelial dysfunction 
markers over time in HIV+ adults.
Hypotheses. As is displayed in 
Figure 1, we hypothesize that 0 to 
12-week changes in insomnia 
symptoms will be positively 
associated with 0 to 12 week 
changes in IL-6, CRP, D-dimer, and 
brachial FMD (H3). We also 
hypothesize that 0 to 12-week 
changes in insomnia symptoms will 
positively predict 12 to 24 week 
changes in IL-6, CRP, D-dimer, and 
brachial FMD (H4). 
Study Design and Sample. We will use 
data from a recently completed 24-week 
RCT (R01 HL126557; co-PIs: Gupta, Stewart, and Freiberg) comparing computerized cognitive-
behavioral therapy (CBT) for depression to usual care. 51 HIV+, ART-treated, virologically 
Table 3. Inclusion and Exclusion Criteria 
Inclusions 
• Screening HIV-1 RNA level <75 copies/mL while on 
ART for ≥1 year 
• Screening PHQ-9 depression score ≥10 
Exclusions 
• History of clinical CVD 
• Treatment for malignancy in last 6 months 
• Uncontrolled diabetes (HbA1c >8.0%) or newly 
diagnosed glucose intolerance (glucose ≥140 mg/dL) 
• Uncontrolled hypertension (>160/110 mmHg) 
• Screening eGFR <60mL/min/1.732 
• Screening total cholesterol >240 mg/dL 
• Pro-inflammatory conditions besides HIV infection 
(hepatitis B or C co-infection is allowed) 
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suppressed adults with a positive depression screen were randomized in a 1:1 fashion (see 
Table 3 for inclusion and exclusion criteria). The primary outcome is brachial FMD, and the 
secondary outcomes are IL-6, CRP, and D-dimer. The 0 to 12-week period is the treatment 
phase, and the 12 to 24-week period is the follow-up phase. The schedule of events is as 
follows: screening visit, two entry visits, computerized CBT (intervention arm only), 12-week 
post-treatment visit, and 24-week follow-up visit. Once eligibility was established at the 
screening visit, participants completed two entry visits, the second of which randomized 
participants. Relevant to the proposed project, insomnia symptoms, inflammation and 
coagulation biomarkers, and brachial FMD were assessed at both entry visits, the 12-week visit, 
and the 24-week visit. The CTSI’s Imaging Core, directed by Dr. Gupta, performed to brachial 
FMD as outlined in consensus guideline recommendations,90 as demonstrated by our previous 
peer-reviewed publications.91-95 The RCT's recruitment end date was 08/31/2018. The scoring of 
questionnaires and FMD ultrasound scans is ongoing, and standard assays for the inflammation 
and coagulation biomarkers will be completed under the direction of Dr. Russell Tracy at the 
University of Vermont shortly following the completion of recruitment. Thus, the RCT data for the 
Aim 2 project will be available fall of 2018.  
Statistical Considerations. Independent variables. The independent variable for H3 and H4 
will be the 0 to 12-week change score for the PSQI global score (12-week PSQI adjusted for 0-
Week PSQI). This variable will reflect treatment phase changes in insomnia symptoms. The 
PSQI is a 19-item scale that yields a global score and seven component scores (sleep quality, 
sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, use of sleeping 
medications, and daytime dysfunction), with research supporting its reliability and validity.96 A 
meta-analysis reported that the PSQI has strong associations with the Insomnia Severity Index 
(r=0.80) and sleep efficiency scores from sleep diaries (r = -0.76), and nonsignificant to small 
associations with the Apnea Hypopnea Index (r=0.11-0.30) and number of oxygen desaturation 
events (r=0.21).97 Moreover, the PSQI measures core symptoms of insomnia disorder as 
defined by the DSM-550: dissatisfaction with sleep quality (sleep quality), difficulty initiating sleep 
(sleep latency), difficulty sustaining sleep (sleep duration, habitual sleep efficiency, sleep 
disturbance), and significant distress or impairment (daytime dysfunction). 
Dependent variables. The dependent variables for H3 are the 0 to 12-week change scores for 
IL-6, CRP, D-dimer, or brachial FMD (12-week marker value adjusted for baseline value). These 
variables will reflect treatment phase changes in each marker. The dependent variables for H4 
are the 12 to 24-week change scores for the four mechanism markers (24-week marker value 
adjusted for 12-week value), which will reflect follow-up phase changes in each marker. 
Covariates. Models will include covariates with the potential to confound associations between 
changes in insomnia symptoms and changes in the markers under investigation. Models will be 
adjusted for the following baseline factors: age (years), sex (0=male, 1=female), race/ethnicity 
(0=White, 1=non-White), Framingham general cardiovascular risk score (FRS; continuous),98 
depressive symptoms (Hopkins Symptom Checklist-20 [SCL-20] without items 12, 16, and 17), 
and randomization status (0=usual care, 1=intervention). A sensitivity analysis will further adjust 
for changes in depressive symptoms. The FRS was chosen because recent evidence suggests 
that this tool most accurately captures risk of CVD events among HIV+ adults, while the 
ACC/AHA Pooled Cohort equations (PCEs), the Systematic COronary Risk Evaluation 
(SCORE), and the Data Collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study 
equation.99 
Data analysis. We will conduct a series of measured-variable path analyses using Mplus. For 
each dependent variable, two separate analyses will be performed. The first analysis will test H3 
and the second will test H4, each adjusting for the baseline factors detailed above. A 
subsequent sensitivity analyses will be performed with the addition of changes in depressive 
symptoms. As is shown in Figure 1, the structural paths between 0 to 12-week changes in 
insomnia symptoms and 0 to 12-week changes in mechanisms markers will be the tests of H3. 
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The structural paths between 0 to 12-week changes in insomnia symptoms and 12 to 24-week 
changes in mechanism markers will be the tests of H4. If these coefficients of these paths are 
significant and positive, it would indicate that as insomnia symptoms decrease so, too, do levels 
of candidate mechanisms underlying HIV-CVD. Although both sets of analyses will provide 
useful knowledge, the tests of H4 will provide a stronger test, as the insomnia changes precede, 
and thus cannot be influenced, by changes in the markers of interest. 
Path analysis is a particularly good fit, as it will allow us to simultaneously create the insomnia 
and marker change variables and use them as independent and dependent variables to test H3 
and H4. To assess model fit, we will use two goodness-of-fit statistics.100 The χ2 statistic 
measures the absolute fit between the hypothesized model and the observed pattern of 
relationships among measured variables. Because a nonsignificant χ2 statistic demonstrates 
that there is no difference between the hypothesized and observed patterns of relationships, it 
indicates that the hypothesized model is acceptable. The root mean square error of 
approximation (RMSEA) statistic adjusts the estimate of absolute fit for the complexity of the 
hypothesized model. Smaller values of RMSEA indicate better model fit, with values less than 
0.06 representing acceptable model fit.101 Parameters will be estimated by full information 
maximum likelihood, which uses all of the observed data and is superior to traditional methods 
of handling missing data.102 
Rigorous nature of the research. The Aim 2 methodology ensures a rigorous and transparent 
approach. First, the prospective nature of the data enables an examination of the directionality 
of associations between insomnia and putative mechanisms of HIV-CVD. Second, the sample 
cohort is well characterized and excludes potential confounders, which reduces the number of 
competing explanations for observed relationships. Third, the data source provides repeated 
measures of insomnia symptoms and multiple mechanisms of HIV-CVD. Fourth, we apply the 
appropriate use of measured-variable path analyses to test associations between changes in 
insomnia symptoms and changes in HIV-CVD candidate mechanisms over time.  
Anticipated Problems, Limitations, Alternative Approaches. In the unanticipated event that 
our hypotheses from Aim 1 and 2 are not supported, we would change our focus to other 
potential mechanisms to which insomnia may contribute, such as poor health behaviors. The 
first limitation of the Aim 2 project is that all participants in the RCT will have screened positive 
for depression. Thus, we view this as a first test of these hypotheses. New data will need to be 
collected to test these hypotheses in a cohort not selected based on depression status, as we 
are not aware of any data sources with repeated assessments of insomnia and candidate 
mechanisms underlying HIV-CVD. The second limitation of the Aim 2 project is a small sample 
size. 
Project Benchmarks 
Aim 1 FA 18 SP 19 SU 19 FA 19 SP 20 SU 20 
Prepare dataset for analysis       
Analyze and interpret data       
Present results at conference       
Submit manuscript for publication       
Aim 2 FA 18 SP 19 SU 19 FA 19 SP 20 SU 20 
Assist in data collection       
Prepare dataset for analysis       
Analyze and interpret data       
Present results at conference       
Submit manuscript for publication       
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PROTECTION OF HUMAN SUBJECTS 
A. Protection of Human Participants (For Observational Study in Aim 1) 
The Human Subjects Research under Aim 1 meets the definition of Human Subjects Research. 
(A1) Risk to Human Subjects 
Human subjects involvement, characteristics, and design. The Veterans Aging Cohort Study 
(VACS) Biomarker Cohort is a cross-sectional biospecimen subsample of the larger VACS 8-
site study, an ongoing longitudinal, prospective multisite observational cohort of HIV+ and 
uninfected veterans beginning in 1999. The VACS Biomarker Cohort subsample was collected 
between 2005-2007 and was designed to examine the associations of HIV-related biomarkers, 
HIV treatment, and comorbid conditions with morbidity and mortality. Aim 1 will utilize data from 
the 1,542 HIV+ participants in the VACS Biomarker Cohort. The majority of the VACS 
Biomarker Cohort participants are men (97%) of a racial/ethnic minority (69% African American) 
and has one or more traditional or non-traditional cardiovascular disease risk factors.     
Sources of materials. The proposed data analysis for Aim 1 will utilize previously collected data 
merged from a number of sources, including VACS study collected blood biospecimens and 
annual survey instruments, clinical and administrative data from VA sources (i.e., immunology 
case registry, corporate data warehouse, and pharmacy benefits management databases), and 
non-VA sources (i.e., Medicare, Medicaid, and National Death Index data). 
Potential Risks. The risks to participants inherent to the proposed study are minimal as the 
proposed study will be analyzing previously collected data from the various sources listed 
above. The primary risk to participants is a loss of confidentiality (i.e., private patient information 
could become known to persons not involved in the research project). The data protection 
practices in place for the VACS data sources minimizes the likelihood of this.   
(A2) Adequacy of Protection Against Risk 
Recruitment and informed consent. The proposed study for Aim 1 will not involve active 
recruitment or enrollment of any new participants. All of the VACS Biomarker participants are a 
part of the larger VACS 8-site parent study and have consented to the use of medical records 
and blood biospecimens in future clinical research efforts. 
Protections against risk. The potential risk of loss of confidentiality has been minimized by a 
number of measures. First, all data files and computer workstations are password protected. 
Second, data management will follow protocols established by the VACS Coordinating Center 
for access to VACS data and integration of additional data elements with VACS data. 
Specifically, an experienced VACS programmer will create a patient level analytic dataset using 
scrambled social security numbers that links existing VACS data (e.g., immunology case 
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registry, annual survey instruments), VACS blood biospecimen analysis, and other databases 
(e.g., Medicare/Medicaid databases). The created analytic database will be de-identified and 
uploaded into a SQL server database for storage, queries, manipulation, and analyses by the 
study analyst. Third, key linking participant identifiers, including scrambled social security 
numbers and participant level study data, will be kept in a password-protected file and accessed 
only by the VACS programmer. Fourth, all VA data will be maintained behind the VA firewall at 
all times and accessed via password-protected folders. Fifth, no data will be transferred 
electronically in order to maximize protection of the data. 
(A3) Potential Benefits of the Proposed Research to Participants and Others 
Due to the observational nature of the study of Aim 1, participants are unlikely to directly benefit 
from the proposed study. However, participants and other HIV+ patients may benefit from the 
scientific knowledge to be gained from this work. 
(A4) Importance of the Knowledge to be Gained 
There is important knowledge to be gained through the completion of Aim 1. No other studies 
currently exist that examine insomnia disorder in relation to inflammation and coagulation and 
insomnia symptoms in relation to coagulation in HIV+ individuals. Results from this Aim could 
suggest an independent association of insomnia symptoms with immune activation, systemic 
inflammation, and coagulation in a large, HIV+ cohort, prompting a need to further investigate 
insomnia’s role in mechanisms of atherosclerotic CVD. 
Again, given the risks to participants are minimal, the value of the knowledge to be gained and 
it’s possible impact on the improvement of care for HIV+ individuals significantly outweigh 
potential risks. Even in the event of negative findings from the current proposal, the results of 
these investigations will substantially add to our current gap in knowledge regarding insomnia 
as a psychosocial risk factor of CVD among individuals with HIV. 
(A5) Data Safety and Monitoring Plan 
Although Aim 1 does not involve a clinical trial, Dr. Freiberg and the VACS study team have a 
data safety and monitoring plan in place. Experienced personnel from the University of 
Pittsburgh and VACS are responsible for the confidentiality, security, and integrity of the 
potentially identifiable data for the study. Access to specific data elements will be granted only 
after Dr. Freiberg verifies that the individual (a) has a need to access the particular data, (b) is 
approved to do so by IRB, (c) is fully compliant with VHA Privacy Policy, Human Subjects 
Protection, and Good Clinical Practices training requirements, and (d) has signed any applicable 
data use agreements. In the event of unauthorized access to study data or other unanticipated 
adverse events the IRB will be notified in a timely fashion. 
To assure the protection of human subjects and to comply with federal and state laws, the 
University of Pittsburgh IRB and the West Haven VA (site of the VACS Coordinating Center) will 
review and approve all aspects of the research project prior to project initiation. All study 
personnel will (a) document completion of the institution-required human subjects training and 
Health Insurance Portability and Accountability Act (HIPPA) privacy training, and (b) abide by 
established policies and procedures (consistent with HIPPA Privacy and Security Rules) for the 
protection of personal health information. All data analyzed in the course of the proposed study 
will be confidential and secure. 
Data center architecture, backup strategies, and physical data storage that will support the 
protection of the data are detailed below: 
Data Center Architecture. The databases for the Coordinating Center are housed on a 
networked array of Dell servers, running Microsoft Server 2008 as the OS and SQL Server 2008 
for database management. The servers are connected to the West Haven campus network of 
gigabit fiber Ethernet backbone and 100-megabit 10-base-T network switches. The network is 
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protected by VA firewalls and monitored for physical and remote intrusions. The network 
systems and data center completed a VA-mandated recertification and an inspection by the 
Inspector General. Security is maintained by a full-time Information Security Officer in 
coordination with VACT IT staff. 
a. Coordinating Center personnel access the servers using Remote Desktop Connections 
and SAS 9.2 or higher using personal computers running Microsoft Windows SP Service 
Pack 3 or higher. The user desktop computers are kept current with existing VA 
requirements for automated updating or virus protection definition files and Microsoft 
Windows XP security patches. Existing VA standards for composition and frequencies of 
changing of passwords for network logins are followed. 
b. The SQL database server resides in a secure server room in the sub-ground level of 
Building 1 at the VA Connecticut Healthcare System’s West Haven campus. The server 
room is fully environmentally controlled and is manned and access-controlled 365 
days/year, 24 hours/day. It is also guarded by combination lock and video surveillance 
systems. The server power is protected by a facility-based uninterruptible power supply 
with a minimum of 6 hours of runtime, with automated clean shutdown capabilities. In 
addition, the power to the entire server room is backed up with diesel generator, which 
powers critical areas of the campus in the event of power failure. The room is further 
protected by inert gas flooding in the event of a fire. 
Backup Strategy. Backups of data will be to a mirror database on Dell PowerEdge servers 
housed in the protected, secure computer room at the VA Connecticut Healthcare System’s 
West Haven Campus. To protect subject and data privacy, all VA-mandated security procedures 
will be maintained on the mirror server as well. Mirroring operations will be performed in concert 
with operations on the main server, as network bandwidth allows. In the event of failure of or 
lack of electrical power or physical access to the main server, operations can continue using the 
mirror server. 
Physical Data Storage. The physical data storage mechanism will be a combination of Direct 
Attached Storage (DAS) and Network Area Storage (NAS). Both DAS and NAS can be 
configured to provide highly redundant and fault-tolerant storage. The study data will be 
organized into a redundant series of time delineated ‘Builds’. Each Build will be stored on 
several storage devices as backup. These Data Center Builds will be placed on the 
aforementioned DAS and NAS devices, each operating under RAID 5 protocols. All hardcopy 
cohort data received and analysis datasets used will be archived in accordance with NIH 
requirements and HIPAA standards. 
B. Protection of Human Subjects (For RCT Study in Aim 2) 
The Human Subjects Research under Aim 2 meets the definition of a phase II clinical trial. The 
parent R01 (R01HL126557) clinical trial is currently registered in ClinicalTrials.gov (Identifier: 
NCT02309372). 
(B1) Risks to Human Subjects 
Human subjects involvement, characteristics, and design. The RCT randomized 51 HIV+ 
virologically-suppressed (HIV-1 RNA <75 copies/mL), depressed (Patient Health Questionnaire 
score ≥10) adults. Specific inclusion and exclusion criteria for the RCT are listed below. There 
were no exclusions based on ethnicity, race, sex, or CD4 cell count. The Indiana University 
Institutional Review Board has approved this study. Participants were recruited from the HIV 
outpatient clinics of Indiana University 
Health-University Hospital, Indiana University Health-Methodist Hospital, Eskenazi Health 
Hospital, and the Roudebush VA Medical Center. All study assessment visits were conducted in 
the Indiana University Health-University Hospital’s Clinical Research Center. For participants 
randomized to the intervention arm, the computerized cognitive behavioral therapy was 
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administered at a private location chosen by the participant that allows Internet access (e.g., 
from participant’s home, from participant’s family/friend’s home, Dr. Stewart’s laboratory offices). 
Inclusions 
• ≥18 years of age 
• Documented HIV infection 
• Screening HIV-1 RNA level <75 copies/mL while on ART for ≥1 year 
• Screening PHQ-9 score ≥10 
Exclusions 
• Current CVD or congestive heart failure 
• Treatment for malignancy (besides localized skin cancers) within 6 months of screening 
• Uncontrolled diabetes (defined as screening Hgb A1c >8.0%) or newly diagnosed glucose 
intolerance (defined as screening glucose ≥140 mg/dL) 
• Uncontrolled hypertension (systolic BP >160 mmHg or diastolic BP >110 mmHg) 
• Screening eGFR <60mL/min/1.732 (using the 2009 CKD-EPI creatinine formula) 
• Screening total cholesterol >240 mg/dL 
• Pro-inflammatory conditions besides HIV infection (e.g. autoimmune diseases, but allowing hepatitis 
B or C co-infection) 
Sources of materials. Data was obtained through existing medical records, blood samples, urine 
samples, ultrasound images, and self-report questionnaires. Medical records were reviewed 
manually for demographics, medical diagnoses, and medications by Dr. Gupta. Blood samples 
were obtained via peripheral venipuncture for testing of chemistries, cell counts, HIV-1 RNA 
levels, CD4 cell counts, inflammatory/coagulatory markers, and metabolic markers. Urine 
samples were obtained via standard clean-catch technique for pregnancy testing. Ultrasound 
images of the brachial artery were measured using high frequency ultrasound images 
downloaded to a secure, encrypted electronic database for testing of endothelial function. Self-
report questionnaires were administered to participants for the assessment of depression, sleep 
quality, anxiety, anger/aggression, positive/negative affect, medication adherence, tobacco use, 
and physical activity. Data is stored in a password-protected computerized database via 
REDCap that includes only the participants’ study identification number (names and other 
identifiable information will not be included). Only the R01 principal investigators, co-
investigators, and research personnel who will directly obtain the necessary data will have 
access to the participant identities. All data obtained for this study was obtained only after 
written, informed consent is provided by each participant. 
Potential risks. The risks to participants inherent to the proposed study are minimal. First, there 
is the possibility of loss of confidentiality. Second, there are risks associated with the blood 
draw/needle stick, such pain, bruising, infection, and phlebitis. Third, there are risks associated 
with the nitroglycerin administration as part of the brachial artery testing, including headache, 
transient hypotension, sensation of flushing of the skin and rash, and pain associated with the 
inflation of the forearm cuff as part of the brachial reactivity testing. Fourth, there is a risk that 
participants may feel uncomfortable completing the questionnaires. There are no known risks 
related to the use of the computerized cognitive behavioral therapy Beating the Blues. The 
principle alternative to these procedures would be to not participate in the research study. 
(B2) Adequacy of Protection Against Risks 
Recruitment and informed consent. The Indiana University Institutional Review Board has 
approved this study (protocol # 1409114254) Participants were recruited from the HIV outpatient 
clinics of Indiana University 
Health-University Hospital, Indiana University Health-Methodist Hospital, Eskenazi Health 
Hospital, and the Roudebush VA Medical Center. If the primary provider for the patient believes 
a patient is eligible for the study and allows the patient to be approached for screening, one of 
the study investigators or a study nurse approached each potential participant during the 
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patient’s regularly scheduled clinic visit. If eligibility was confirmed, then the purpose, 
procedures, and risks and benefits of the study were discussed with the participant. Participants 
had ample opportunity to ask questions and to have all concerns addressed. If the participant 
wished to pursue screening, then written informed consent was obtained (and a copy given to 
the participant). All consent forms are stored in a locked file cabinet. 
Protections against risk.  
a) Confidentiality. In order to minimize the risk to participant’s loss of confidentiality, 
identifying information will be removed from all participant data once it is abstracted and 
recorded. We will only use the random study identification number (generated when 
consent is provided). All hard copies of study data will be kept in a secure and locked 
cabinet. All electronic copies of study data will be kept in a password protected computer 
database (i.e., REDCap). The master linking list between the patient identifiers and the 
random study identification number will be kept in a separate secure and locked cabinet 
than the hard copy data. Identifiers will never be used in the analysis or presentation of 
study results. 
b) Blood draws. In order to minimize the risk to participants from the blood draw/needle 
stick, only trained medical personnel will perform the procedure. The amount of blood to 
be collected falls within the safety standards for blood donation. 
c) Nitroglycerin. All brachial artery reactivity testing will be performed in a controlled setting 
at the Indiana University Health-University Hospital’s Clinical Research Center. In order 
to minimize the risk to participants of the nitroglycerin administration, registered CRC 
nurses will monitor the participant’s blood pressure throughout the brachial reactivity 
testing. Participants with inherent resting hypotension will be excluded from the NTG-
mediated flow dilation portion of the brachial reactivity testing. If the participant becomes 
symptomatic (e.g. dizzy, perspiring, weak or nauseated, or if the systolic blood pressure 
falls below 80mmHg or more then 30mmHg below their baseline systolic blood pressure, 
the study will be stopped immediately), the patient will be placed in Trendelenberg 
position. If the blood pressure does not recover spontaneously, fluids will be given 
through the previously placed IV heplock. If the patient develops a headache, an 
analgesic will be recommended. In addition, participants with recent use of 
phosphodiesterase inhibitors (e.g. erectile dysfunction medications) prior to NTG 
administration or planned use after NTG administration will be excluded with the study 
visit to be rescheduled. 
d) Questionnaires. In order to minimize the risk to participants as a result of becoming 
uncomfortable during questionnaire administration, participants will complete 
questionnaires in a private setting. In addition, a trained study team psychology 
personnel will be available to address any questions regarding completion of the 
questionnaires. 
e) Suicidality. Although not an inherent risk to participation in the study, eligible participants 
have a probable depressive disorder as indicated from completion of the PHQ-9. As 
such, these participants may report suicidal ideation at screening or develop suicidal 
ideation during the course of the study. We have already put into place a protection 
protocol for just this event in our previous studies in HIV-uninfected depressed patients. 
If a participant reports having thoughts of being better off dead or of hurting him/herself 
(i.e., responds with a 1, 2, or 3 to PHQ-9 Item #9 or spontaneously reports suicidal 
ideation), the study visit will stop and the Suicidal Ideation Protection Protocol of the 
parent RCT will be initiated. This protocol requires the interviewer to complete the 
Patient Suicidality Form, which asks the participant if s/he (1) has a suicide plan, (2) has 
been struggling against thoughts of suicide, and (3) has attempted suicide in the past. If 
the participant answers “no” to all three suicide questions, the visit will proceed as 
normal and the completed Patient Suicidality Form will be given to the principal 
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investigator. If the participant answers “yes” to any of the three questions, the research 
team member will escort the participant to the Crisis Intervention Unit at the Eskenazi 
Health Hospital Emergency Department (located one block away from the Indiana 
Clinical Research Center) for a formal mental health evaluation. Participants who require 
a formal mental health evaluation will be withdrawn from the study. If an enrolled 
participant reports having thoughts of being better off dead or of hurting him/herself 
during any telephone calls (e.g., a scheduling call or a call to the study team initiated by 
the participant), the participant will be given three local crisis intervention numbers and 
strongly encouraged to call. 
(B3) Potential Benefits of the Proposed Research to Participants and Others 
There are a number of potential benefits to participants in the clinical trial we propose to use. 
First, participants will receive an evaluation of their cardiovascular and immunologic status. 
Second, participants randomized to the intervention arm may derive short-term benefits from the 
Beating the Blues depression treatment program, although this is not guaranteed. Third, 
participants may benefit from knowing that their participation will accrue potentially beneficial 
knowledge to other HIV+ patients. 
The standard of care for the usual care arm will remain unaltered and the Beating the Blues 
depression treatment program used in the intervention arm is safe and has the potential to 
provide clinical benefits. In addition, the impact of the potential risks on participants has been 
minimized. Thus, the ancillary benefits to the participants in the clinical trial significantly 
outweigh the minimal risks in this study.  
(B4) Importance of the Knowledge to be Gained  
There is important knowledge to be gained through the completion of Aim 2. No studies 
currently exist that examine changes in sleep quality and changes in inflammation, coagulation, 
and FMD in HIV+ individuals. Results from this study could suggest that insomnia is a potential 
novel target for future efforts to reduce CVD in HIV. In fact, positive results from the proposed 
research project would serve as preliminary evidence that insomnia may be a causal and 
modifiable driver of inflammation, coagulation, and endothelial dysfunction in people with HIV 
and, thus, would support the mechanistic rationale for a future RCT testing whether treating 
insomnia in people with HIV helps to prevent clinical CVD onset. 
Again, given the risks to participants are minimal, the value of the knowledge to be gained and 
it’s possible impact on the improvement of care for HIV+ individuals significantly outweigh 
potential risks. Even in the event of negative findings from the current proposal, the results of 
these investigations will substantially add to our current gap in knowledge regarding insomnia 
as psychosocial risk factor of CVD among individuals with HIV. 
(B5) Data Safety and Monitoring Plan 
Due to the active R01’s phase II clinical trial status, a formal Data and Safety Monitoring Board 
is not required; however, a data and safety monitoring plan (DSMP) has been implemented. The 
DSMP consists of study progress reports every 6 months monitoring data security, participant 
enrollment, protocol deviations, and all serious adverse events (SAE). The progress report is 
reviewed by a panel including the R01 PI’s (Drs. Gupta, Stewart, and Freiberg), the study 
biostatistician (Dr. Ziyue Liu; Department of Biostatistics, Indiana University School of Medicine 
and School of Public Health), and an expert investigator at Indiana University not directly 
connected with the study (Dr. Allon Friedman; Division of Nephrology, Indiana University School 
of Medicine). Any study participants prematurely discontinued due to a SAE will be reviewed 
immediately. Standard procedures for reporting study protocol deviations will be implemented 
for Indiana University Clinical Research Center, IRB, and NHLBI. SAEs will be reported to the 
IRB within 30 business days and subsequently forwarded to the NHLBI as required.
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INCLUSION OF CHILDREN 
The VACS Biomarker Cohort being utilized in Aim 1 does not include individuals under the age 
of 18. Those under the age of 18 were excluded from participation in VACS data collection as 
recruitment targeted active duty or veteran status military employees utilizing Veterans Affair 
(VA) services, which only includes those over the age of 18. 
 
The active RCT utilized in Aim 2 will not include individuals under the age of 18. Individuals 
under the age of 18 are excluded on the basis of potential confounding of hormonal fluctuations 
during adolescence on the proposed endpoints of inflammation, coagulation, and endothelial 
function. 
INCLUSION OF WOMEN AND MINORITIES 
The epidemiologic study proposed in Aim 1 and the RCT proposed for use in Aim 2 do not have 
exclusion criteria based on gender, race, or ethnicity. 
Based on the R01’s (R01HL126557) co-investigators cumulative experience and the HIV+ 
population cared for at the proposed recruitment sites (i.e., Indiana University Health-University 
Hospital, Indiana University Health-Methodist Hospital, Eskenazi Health Hospital, and the 
Roudebush VA Medical Center), the study subjects are anticipated to be approximately 25% 
women, 40% African American, and 10% Hispanic. American Indians, Alaskan Natives, Asians, 
and Native Hawaiians or Other Pacific Islanders are not expected to be represented in the 
clinical trial due to extremely low representation of these groups within the Indiana University 
health Hospitals HIV outpatient clinics and the general Indianapolis area. 
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Hopkins Symptom Checklist-20 (SCL-20) 
 
Below is a list of problems and complaints that people sometimes have. Please read each one 
carefully. After you have done so, please check one of the spaces to the right that best 
describes HOW MUCH THAT PROBLEM HAS BOTHERED OR DISTRESSED YOU DURING 
THE PAST WEEK, INCLUDING TODAY. Mark only one space for each problem and do not skip 
any. 
 
How much were you bothered by: 
 
Not at all A little bit Moderately 
Quite a 
bit 
Extremely 
1. Loss of sexual interest or 
pleasure 
    
2. Feeling low in energy or 
slowed down 
     
3. Thoughts of ending your life      
4. Poor appetite      
5. Crying easily      
6. Feeling of being trapped or 
caught 
     
7. Blaming yourself for things      
8. Feeling lonely      
9. Feeling blue      
10. Worrying too much about 
things 
     
11. Feeling no interest in 
things 
     
12. Trouble falling asleep      
13. Feeling hopeless about the 
future 
     
14. Thoughts of death or dying      
15. Overeating      
16. Awakening in the early 
morning 
     
17. Sleep that is restless or 
disturbed 
     
18. Feeling everything is an 
effort 
     
19. Feelings of worthlessness      
20. Feelings of guilt      
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Pittsburgh Sleep Quality Index (PSQI) 
 
The following questions relate to your usual sleep habits during the past month only. Your 
answers should indicate the most accurate reply for the majority of days and nights in the past 
month. Please answer all questions. 
 
1. During the past month, what time have you usually gone to bed at night? 
 
BED TIME ___________ 
 
2. During the past month, how long (in minutes) has it usually taken you to fall asleep each 
night? 
 
NUMBER OF MINUTES ___________ 
 
3. During the past month, what time have you usually gotten up in the morning? 
 
GETTING UP TIME ___________ 
 
4. During the past month, how many hours of actual sleep did you get at night? (This may 
be different than the number of hours you spent in bed.) 
 
HOURS OF SLEEP PER NIGHT ___________ 
 
For each of the remaining questions, check the one best response. Please answer all questions. 
 
5. During the past month, how often have you had trouble sleeping because you… 
 
 Not during 
the past 
month 
Less than 
once a week 
Once or 
twice a week 
Three or 
more times a 
week 
a. Cannot get to sleep within 30 
minutes 
   
b. Wake up in the middle of the 
night or early morning 
    
c. Have to get up to use the 
bathroom 
    
d. Cannot breathe comfortably     
e. Cough or snore loudly     
f. Feel too cold     
g. Feel too hot     
h. Had bad dreams     
i. Have pain     
j. Other reason     
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6. During the past month, how would you rate your sleep quality overall? 
 
Very Good 
Fairly Good 
Fairly Bad 
Very Bad 
 
7. During the past month, how often have you taken medicine (prescribed or “over the 
count”) to help you sleep? 
 
 Not during the past 
month 
 Less than once a 
week 
 Once or twice a 
week 
 Three or more 
times a week 
8. During the past month, how often have you had trouble staying awake while driving, 
eating meals, or engaging in social activity? 
 
 Not during the past 
month 
 Less than once a 
week 
 Once or twice a 
week 
 Three or more 
times a week 
 
9. During the past month, how much of a problem has it been for you to keep up enough 
enthusiasm to get things done? 
 
No problem at all 
Only a very slight problem 
Somewhat of a problem 
A very big problem 
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Framingham Risk Score 
 
Risk Factor Risk Points 
 Men Women 
Age   
30-34 0 0 
35-39 2 2 
40-44 5 4 
45-49 6 5 
50-54 8 7 
55-59 10 8 
60-64 11 9 
65-69 12 10 
70-74 14 11 
75+ 15 12 
HDL-C   
60+ -2 -2 
50-59 -1 -1 
45-49 0 0 
35-44 1 1 
<35 2 2 
Total Cholesterol   
<160 0 0 
160-199 1 1 
200-239 2 3 
240-279 3 4 
280+ 4 5 
Systolic Blood Pressure 
(mmHG) 
Not treated Treated Not treated Treated 
<120 -2 0 -3 -1 
120-129 0 2 0 2 
130-139 1 3 1 3 
140-149 2 4 2 5 
150-159 2 4 4 6 
160+ 3 5 5 7 
Smoker 
No 0 0 
Yes 4 3 
Diabetes 
No 0 0 
Yes 3 4 
Total Points:   
 
 
Adapted from: 
D’Agostino, RB, Vasan, RS, Pencina, MJ, et al. General cardiovascular risk profile for use in 
primary care: the Framingham Heart Study. Circulation. 2008; 117(6): 743-53. 
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HIV-Depression Trial 
 
CONSORT 2018 Flow Diagram 
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